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Chloroquine is a widely used antimicrobial and anti-inflammatory drug which
exhibits toxicity towards microbes by preferential accumulation in the acidic digestive
vacuole. It is known to inhibit both DNA and RNA polymerases, protein and lipid
synthesis, and interferes with the excision repair mechanisms, however, it’s biochemical
and cytotoxic mode of action is not clearly understood. The purpose of this investigation
was to determine the cytotoxic, biochemical, and genotoxic effects of chloroquine on
human host cells using AHH-1 lymphocytes as surrogate mammalian cells.
Cells were grown in supplemented RPMI-1640 and exposed to serially diluted
chloroquine concentrations ranging between 0 and 0.8 mM for 1 to 168 h. Cell proliferation
was assessed by counting with a hemocytometer and viability was determined by the MTT
and Acid Phosphatase assays. The distribution of viable, apoptotic and necrotic cells was
determined by staining with propidium iodide and fluorescein diacetate and by using flow
cytometry. Chromosomal aberration and membrane integrity were assessed by the
micronucleus assay and cellular lactate dehydrogenase activity, respectively.
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Morphological characteristics were examined by electron microscopy.
Chloroquine exposure (0.2 mM and 0.6 rtiM) caused an 80% deerease in cell eounts
after 24 h. The MTT assay showed a 58% to 94.5% viable cell loss at 0.2 mM and 0.6
mM, respectively, after 48 h treatment. Acid phosphatase activity increased 50% and
60% at 0.4 mM and 0.6 mM dosages, respectively, after 24 h, and declined 33% after
48 h. Flow cytometric analysis showed a 22% decrease in viable cell numbers, 17%
increase in the apoptotic cell population, and a 5-fold increase in necrotic cell numbers
showed, after 24 h of exposure. Although, cell eycling progression was not affected, a
dose-dependent increase of 5% at 0.8 mM was observed for micronucleus formation.
Laetate dehydrogenase aetivity levels peaked in the growth media at 0.3 mM, after 72 h
exposure compared to the eontrol. The electron microscopic analysis showed evidenee of
increased vacuolization, multilamellar body formation and membrane disruption with
premature cell lysis. These studies suggest that chloroquine is cytotoxic to AHH-1 cells at
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The bark of the Cinchona tree is known to possess a remarkable compound, quinine
(quinine sulfate) whose medicinal properties were recognized by the Peruvian Indians as far
back as the 1600's. Isolated in the pure form by French chemists Pelletier and Caenton in
1820, quinine was used as the only specific drug, a prophylactic and cure for malaria, until
the 1930's. However, during World War II, quinine was supplanted by quinacrine, which
was in turn replaced by chloroquine (CQ) and primacrine, the present drugs of choice. The
4-aminoquinoline, chloroquine, is a synthetic derivative of quinine (quinine sulfate) first
synthesized in Germany in 1934. Since the 1940's chloroquine has been successfully used
as an anti-malarial and anti-inflammatory drug in the therapy of various conditions
including lupus erythromatous (systemic and discoid), amebiasis, sclerodermatoid arthritis,
pemphigus lichen plamus and rheumatoid arthritis (McCallister et al., 1987; Morrow et
al.,1989).
The therapeutic use of chloroquine has not been without incident. As early as the
1950's documented reports of chloroquine-associated toxicity include cardiotoxicity that
resulted in death (Nelson & Conlin, 1950, Chaumont A.J., 1966). More recently it has
been observed that chloroquine causes an accumulation of lipid products in the retina and
cornea leading to cataract formation and eventually resulting in blindness (McCallister et
al., 1987). Other findings relate chloroquine usage to nephrotic, neuropathic and teratogenic
defects (Nelson& Conlin, 1950; Sanghvi & Mathur, 1965; Udalova, 1967; Ojewole, 1976;
Sofola, 1980; McCallister, et al., 1987).
In vitro studies, using cultured hepatocytes, demonstrate a drug-induced lipidosis
and cytotoxicity (Lullman et al., 1978). Biochemical analysis shows that chloroquine-
induced lipidosis is a generalized phenomenon and not restricted to particular tissues.
However, pharmacokinetic studies of chloroquine show preferences for certain
organs such as the heart, eye, nerve, and kidney. Morphological findings in both animals
and humans show lipidosis-like alterations in cells. Of particular interest are the
lymphocytes, which are easily available for ultrastructural examination and are particularly
sensitive to the drug in showing generalized lipid storage.
Chloroquine has a high affinity for the acid vesicles such as the lysosome, where
it readily accumulates. Here it is protonated and retained, altering the local pH toward
alkalinity. The altered pH inhibits primarily hydrolytic and lipolytic proteases within the
lysosome. As a result, protein and lipid metabolism are disrupted in the cell. Other effects
include the disruption of endosome and lysosome biosynthesis, receptor recycling,
trafficking and degradation of macromolecules from the endoplasmic reticulum,
intralysosomal digestion and formation ofpolar phospholipid complexes. The phospholipid
complexes are stored within the lysosome leading to the swelling of this vesicle due to
increased osmotic pressure. This gives rise to vacuolization, sometimes occurring with
inclusions of cytoplasmic organelles such as mitochondria. Chloroquine also causes
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enzyme release from the acidic vesicle into the cytoplasm.
Chloroquine has been shown to exert an inhibitory effect on calcium metabolism and
the mitochondrial energy system (Essien & Ette, 1985). The anti-inflammatory effects of
chloroquine have been shown to arise from chloroquine’s ability to decrease the secretion
of tumor necrosis factor (TNF), prostaglandin Ej, IL-1 and IL-6 have also been shown to
be suppressed by the chemical. Chloroquine is known to intercalate within DNA from
various sources (mammalian, parasitic and bacterial), and can result in the inhibition ofboth
RNA and DNA synthesis. In vitro studies show that whereas 0.05mM chloroquine resulted
in the inhibition of the growth of thymocytes, ImM chloroquine resulted in 50% cell death
in thymocytes after a few hours of incubation. Chen and Leonard (1984) showed that cell
death occurred in mouse thymocytes exposed to 0.05mM chloroquine after 1-3 days of
incubation.
The literature abounds with evidence regarding the cytotoxic effects of the drug
on mammalian cells in vitro. Most work has focused on the function of the cellular
vacuolar system because of chloroquine’s known effects of disrupting endocytosis,
exocytosis and lysosomal function due to the alkalinization of the intravesicular pH. It is
generally accepted that the main effect of low concentrations of chloroquine (and related
alkylamines) on mammalian cells is an increased pH of the normally acidic intracellular
vacuoles, endosomes and lysosomes, causing changes in vesicular transport, enzymatic
activity (De Duve et al.,1974; Krogstad & Schlesinger, 1986) and increased
phospholipidosis, which are reversible. Chloroquine is also known to inhibit DNA synthesis
and repair in cell-free systems.
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In spite of the toxic effects, chloroquine remains the drug of choice in most
countries for the treatment of malaria and anti-inflammatory disorders. Although, the
chemical and biochemical effects of the drug have been well documented, there is limited
information as to the toxic mechanism of the compound at the cellular, biochemical and
molecular levels. This study is an attempt to establish a dose-effect relationship regarding
adverse effects of chloroquine and metabolites of this drug under in vitro conditions using
the latest testing methods.
A. Broad Objectives
Using a human lymphocyte cell line, we assessed the in vitro toxicity ofchloroquine
and attempted to link it with the damage that may occur at the molecular level. The
investigation encompassed both genotoxicity and cytotoxicity as well as biochemical
effects due to chloroquine exposure.
B. Specific Aims
1. Under the genotoxic and cytotoxic indices the following were investigated:
(a) Cell viability and proliferation
(b) Cell cycle progression and clastogenic effects
(c) Alteration of cell morphology
2. Biochemical effects on key enzyme systems including;
(a) Lactate Dehydrogenase - an index for measuring membrane integrity.
CHAPTER 2
REVIEW OF LITERATURE
Chloroquine, a 4-aminoquinone [7-chIoro-4-(4'-diethylamino-1-methyl butylamino)
quinoline], was first synthesized in its pure form in Germany in 1934 by the condensation
of 4, 7-dichIoroquinoline with I-diethylamino-4-aminopentane (Wiselogle, 1964).
A. Physico-chemical Attributes
1. Structure
Chloroquine is a double ringed structure, C,gH26CIN3(see Figure I), linked to a nine
carbon side chain with a molecular weight of 319.89 and a melting point of 87°C. Early
work on the chemical indicated that chloroquine exists as a doubly protonated cation in
aqueous solution at physiological pH (Irvin and Irvin, 1947) and that in this molecular form
it binds to nucleic acids (Parker and Irvin, 1952). Chloroquine is a diprotic weak base. It
has pKgl = 8.1 and p¥^2 = 10.2 and a maximal optical density reading at 365m/U (Allison
et al, 1965). Parker and Irvin (1952) showed that a stepwise addition of small increments
of native calf thymus DNA to a solution of chloroquine at constant concentration and a pH
of 5.9 resulted in a progressive depression of the absorption peaks of chloroquine and a
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shift of these peaks toward longer wavelengths until a limit was reached, the spectrum of
which represented a completely bound ligand. They measured the binding of chloroquine
to DNA using UV-light absorbance and found inhibition at high ionic strength. This
suggested the involvement of ionic forces in the binding. The shift in the spectrum of
chloroquine implied that there was more than electrostatic attraction involved in the
binding and suggested a possible charge transfer. These results were later confirmed by
Stollar and Levine (1962) who observed a decrease in the fluorescent binding of
chloroquine to DNA.
2. Chloroquine Derivatives
Chloroquine is available as both a phosphate and sulphate salt. The diphosphate salt
(CjgHjjClNjOgPj) is made up ofdimorphic, colorless crystals which are bitter to taste. It has
two forms with the melting points ranging between 193-195®C and 215- 218°C. It is freely
soluble in water having an acidic pH of 4.5 in a 1% solution. It is less soluble at neutral
and alkaline pH and is insoluble in organic solvents such as alcohol, benzene, chloroform
and ether. The sulphate derivative, C,8H2gClN304S, is marketed under the name Nivaquine
as an antimalarial drug and is also used in the treatment of various connective tissue
disorders (Bradley-Moore et al., 1985; Ostensen, 1985).
B. Uses
1. Clinical Applications
Chloroquine is used primarily as an antimalarial drug (Barret-Conner, 1978;
McChesney and Fitch, 1984) and sometimes as an anti-inflammatory agent. Malaria is
a tropical parasitic disease known to infect 200-400 million people globally, of whom 10%
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die of the disease in adulthood. Childhood mortality is about 50%. About a third of the
world's population is threatened by the disease (Considine and Considine,1995).
Chloroquine is useful in the treatment of inflammatory ailments such as lupus
erythematosus, amebiasis, sclerodermatoid arthritis, pemphigus lichen plamus, rheumatoid
arthritis and polymyositis sarcoidosis (Morrow et al, 1989; McCallister et al, 1987).
The dosage of chloroquine phosphate in acute malaria attack for an adult and child
is as follows : Initial Dose (day 1) = 600mg/kg and lOmg/kg; 6 hours later = 300mg/kg and
5mg/kg; day 2 - 300mg/kg and 5mg/kg; and day 3 = 300mg/kg and 5mg/kg body weight.
In cases of chloroquine poisoning, it was found that ingestion of 5gm and above of
chloroquine phosphate was fatal and resulted in blood levels of 25 nmol/L (Riou B. et
al.,1988).
Chloroquine levels in blood during chronic treatment of patients with rheumatoid
arthritis ranged between 36.6 to 3895 ng/ml. This includes the racemic chloroquine and
main metabolites, desethylchloroquine and bisdesethylchloroquine, which were present in
the blood as 47.7% and 12.9%, respectively (Augustijns P., 1992).
C. Mode ofAction
Chloroquine readily permeates membranes surrounding acidic vesicles such as the
lysosomes where it accumulates due to an increase in the local pH (Unanue, 1984). The
accumulation of the weak base occurs in the lysosomal interior where a low pH is
maintained by an ATP-dependent proton pump. Extracellularly a neutral species,
chloroquine moves passively in the cytosol and eventually permeates the lysosomal
membrane within which it is retained. Due to the impermeable nature of the lysosomal
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membrane to cations the chemical is unable to escape the confines of the acidic vesicle
once inside (Crabb, 1980). However, it has been observed that the uptake of chloroquine
into lysosomes is temperature-dependent (Crabb, 1980). Lysosomal membranes show an
increased permeability to cations at low temperatures (4°C) which allows the proton
gradient to collapse.
In the treatment of malaria, chloroquine accumulates in the parasite-infested
erythrocyte of the host. It then binds to ferric protoporphyrin IX forming a complex which
is toxic to the parasite incubating within. The chloroquine-sensitive parasite feeds mainly
by phagocytosis. In the process of feeding it engulfs hemoglobin complexed with
chloroquine into its digestive vacuole (Veignie and Moreau, 1991). The digestive vacuole
of the parasite, which is acidic and contains hydrolases, concentrates chloroquine
approximately 800-fold but is primarily responsible for the degradation of the host's
hemoglobin, the parasite's main source of nutrients (Slater and Cerami, 1992). The
breakdown of hemoglobin releases large amounts of the toxic heme moiety,
ferriprotoporphyrin IX (FPIX), which is normally detoxified by polymerization into pigment
bodies (called hemozion) by the parasite's heme polymerase, an enzyme found exclusively
in the acid digestive vacuole. Chloroquine inhibits the heme polymerase, found in the
digestive food vacuole of chloroquine-sensitive parasites at concentrations of 0.12 mM.
Inhibition of heme polymerase blocks the detoxification of ferriprotoporphyrin IX
which poisons the food vacuole (Wellems, 1992). The parasite is starved as a result. Some
investigators suggest that chloroquine interacts with the genetic material of the parasite
and intercalates between the base pairs of the double stranded DNA and inhibits both the
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DNA and RNA polymerases (Rollo, 1970; McChesney and Fitch, 1984) resulting in the
disruption of the parasite's gene expression machinery and the eventual destruction of the
parasite. Other workers (Slater and Cerami, 1992; Wellems,1992) maintain that the
inhibition of heme polymerase as a result of the active accumulation of the drug in the
parasite’s food vacuole is the biologically relevant mode of action.
D. Metabolism
Williams (1959) reported that orally administered hydroxychloroquine is poorly
absorbed. He reported the isolation of 40% of the administered dose from blood. It was
shovsm that 30% of the drug was unchanged and 10% was identified as the major
metabolite, 7-chloro-4-[4'-(ethylamino)-r-methylbutyl]aminoquinoline
(desethylchloroquine). In biological fluids (blood, plasma, urine) four metabolites have been
identified: desethylchloroquine, bisdesethylchloroquine, a 4'-aldehyde compound and a 4'-
carboxy compound. The 4' aldehyde is reduced to the alcohol to a minor extent
(McChesney et al, 1965).
After oral administration, chloroquine is rapidly de-ethylated in the blood to a
secondary amine, desethylchloroquine or desethylhydroxychloroquine (30-40% of blood
chloroquine concentration) and then the primary amine, bisdesethylchloroquine, 5-10% of
blood chloroquine concentration (McChesney and Carson, 1966; Gustafsson et al., 1983)
and the 4'-aldehyde. The 4'-aldehyde is reduced to the alcohol in man as aminor derivative,
but in monkeys it is largely converted to the 4'-carboxy compound. 4-amino-7-
chloroquinoline appears to be a very minor degradation product of chloroquine and
hydroxychloroquine. The major metabolite, desethylchloroquine, possesses antimalarial
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activity against Plasmodiumfalciparum (Aderounmu, 1984) and is toxic (McChesney and
Fitch, 1984). Minor metabolites of chloroquine include carboxylic acid derivatives and
other as yet uncharacterized metabolites which have been found in small amounts
(Aderounmu et al., 1984; Ette et al., 1989).
Ducharme II and Farinotti (1996) have also demonstrated that 60% of a
chloroquine dose is bound to plasma proteins and it is equally cleared by the kidney and
liver. Following administration, chloroquine is rapidly dealkylated via the cytochrome P450
enzymes to the pharmacologieally active desethylchloroquine and bis-desethylchloroquine
which form 40% and 60%, respectively, of the parent chloroquine concentration.
Preliminary data show that cytochrome CYP3A and CYP2D6 isoforms have been found
to affect or be involved in chloroquine metabolism (Ducharme II &. Farinotti, 1996). Both
chloroquine and desethylchloroquine have a half-life of 20 to 60 days.
The various optical isomers of chloroquine bind to plasma albumin, alpha-1-acid-
glycoprotein and DNA (Blaschke et al., 1978; Ofori-Adjei et al., 1986). The above results
were shown by McChesney et al. (1967) and confirmed by Gustafsson et al. (1983) using
different analytical tools. Ansai and Craig (1994) reported the isolation of 55% of the
administered dose; 38.5 - 46% as the unchanged drug and 12.0 - 12.65% as
desethylchloroquine, which showed very high optical activity [a]D^145° in the metabolite.
Chloroquine, is usually administered as racemic diphosphate. Optical isomers of
chloroquine (Blaschke et al., 1978; Craig, 1988) differ in their binding to plasma, albumin,
alpha-1- acid glycoprotein (Ofori-Adjei et al, 1986) and DNA (Fink et al, 1979). The (+)-
isomer is known to show lower toxicity compared with the (-)-isomer (Haber Korn et al..
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1979; Fu, 1986). Stereoselective renal clearance has been observed (Ofori-Adjei et al,
1986). Chloroquine S(+) is preferentially metabolized (Ducharme II and Farinotti, 1996).
An additional metabolite of chloroquine has been identified by chemical ionization
mass spectrometry as N-acetyldesethylchloroquine, but it has never been isolated (Brown
et al., 1984). The major metabolite desethylchloroquine has been shown to have the
absolute (S)-(+)-configuration and the minor metabolite N-acetyldesethylchloroquine has
been prepared in both the racemic and the (S)-(+)-forms.
E. Distribution and Routes of Excretion
1. Distribution
Chloroquine is absorbed from the gastrointestinal tract and is concentrated in the
liver, kidney, heart and brain while strongly bound in melanin-containing cells such as the
eyes and skin (Okumura et al, 1975). The drug is extensively distributed with a volume
distribution of200 to 800 L/kg when calculated from plasma concentrations and 200 L/kg
when estimated from whole blood data. Chloroquine is eliminated very slowly and may
persist in the blood for prolonged periods (Ducharme and Farinotti, 1996). Up to 70% of
a dose may be excreted unchanged in the urine. Renal excretion is enhanced by urinary
acidification. Despite its lipophilic character (Okumura et al, 1975) chloroquine is
effectively excluded from the lumen of the seminiferous tubules and epididymis by the
blood- testis and blood-epididymal barriers, respectively (Dym and Fawcett, 1970; Agrawal
and Hoffer, 1989). Studies have shown a mean ratio of desethylchloroquine to chloroquine
concentration of 9.5 ± 1.9% (i.e. a range from 7.8 to 12.6). This indicates that the




Chloroquine is excreted in the urine and through the milk of lactating mothers.
A nursing infant may consume approximately 0.55% of a 300 mg maternal dose. The
milk : blood ratio of the nursing mother has been estimated to be 0.358 (Drug Facts and




Chloroquine is known to inhibit proteolysis (Cornell et al, 1974) and intracellular
lipolysis (Wibo and Poole, 1974). It inhibits proteolysis in macrophages, fibroblasts, and
hepatocytes (Cornell, 1974; Wibo and Poole, 1974). The elevation of the interior pH of the
lysosome due to protonation of the chloroquine molecule leads to an increase in the interior
pH above the optimum for the proteolytic enzymes. This inhibits the degradative action of
acid proteases present in this vesicle and results in a reduction in the bioavailability of amino
acids required for such metabolic events as gluconeogenesis (Crabb, 1980). The inhibition
of the release of amino acids is noted as the primary effect of chloroquine (Crabb, 1980).
These investigators have shown that chloroquine inhibits the malate-aspartate shuttle
required for the movement of reducing equivalents into the mitochondrion during lactate
gluconeogenesis, ethanol oxidation and glycolysis (Crabb, 1980).
Chloroquine has non-specific effects at high concentrations (i.e. 1 mM and above)
but specifically inhibits lactate gluconeogenesis at low concentrations. The redox potential
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of the cytosolic compartment, as seen by lactate/pymvate ratios obtained from hepatocytes
of 48 h fasted and meal-fed rats exposed to the chemical, is increased by addition of
chloroquine to the cultured cells (DeirAntone,1979). The inhibition of ethanol oxidation
is said to result from the direct increase in the NADH/NAD^ ratio in the cytoplasm with
inhibition of the enzyme alcohol dehydrogenase (Dell'Antone,1979). Thus, chloroquine has
the ability to adversely affect glucose metabolism and ultimately regeneration of energy
(ATP).
The inhibition ofproteolysis by chloroquine is reversed by lysine or ammonia but
not by oleate or carnitine (Dell'Antone, 1979). Seglen et al. (1976,1979) have shown that
ammonium ion blocks proteolysis in isolated liver cells. Insulin and amino acids such as
phenylalanine, proline, methionine and tryptophan in combination, suppress proteolysis in
the perfused liver (Mortimore et al., 1970,1973). It was demonstrated that the inhibitory
effects of chloroquine are increased in vitro when the concentration of cells in suspension
for a fixed initial concentration of chloroquine is increased.
Recent reports indicate that chloroquine affects glucose homeostasis and
chloroquine treatment has been associated with hypoglycemia in rats and humans (Asamoah
et al., 1990). Chronic chloroquine treatment in rats resulted in enhanced insulin secretion
and degradation in target tissues (Asamoah etal,. 1990). Studies on the isolated perfused
heart of rabbit showed that chloroquine acts as a cardiodepressant by causing the decrease
in mitochondrial calcium binding and accumulation by altering the heart mitochondrial
membrane’s ability to bind and accumulate calcium (Essien and Ette, 1986). Also, an in
vitro study suggested that chloroquine has a direct toxic effect on sperm. Sperm motility in
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rats showed a decrease upon exposure to chloroquine resulting in a dose-dependent decrease
in fertility of these rats. This has been attributed to the inhibitory action of chloroquine on
calcium mobilization and consequently on the mitochondrial energy system of the sperm
(Ebeigbe et al.,1986; Okanlawon et al.,1993).
(b) Lipolysis
The enzymes concerned with both proteolysis and lipolysis are located within the
lysosome. Chloroquine affects sterol biosynthesis possibly by the inhibition of available
lipases. Chloroquine is known to inhibit the degradation of endocytosed lipoproteins like
LDL and by that mechanism affects the suppressive effect of LDL on HMG-CoA reductase
involved in squalene synthesis (Chen and Leonard, 1984).
(c) Fatty Acid Synthesis
Chloroquine also exerts an inhibitory effect on cholesterol biosynthesis (Beyen et al.,
1981). In the above study, isolated hepatocytes exposed to chloroquine showed no effects
on fatty acid synthesis. In addition, 10 pM or more of chloroquine were shown to inhibit
the incorporation of '''C-acetate into sterols in mouse L cells but had no effect on fatty acid
synthesis and COj production from the same substrate even with a 10-fold increase in
chloroquine concentration.
Another significant effect of chloroquine is that it stabilizes the surrounding
lysosomal membrane in vitro by binding to it (Weissmann, 1965), increasing it's ability to
contain lysosomal digestive enzymes and to protect the surrounding cytoplasm against
damage from these enzymes. Such effects can also be accomplished by a variety ofsteroids
and other lipid-soluble substances (eg., cortisone and hydrocortisone). There is also
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evidence of in vitro labilization (Filkins, 1969).
(d) Lysosomal pH
In 1978, Ohkuma and Poole showed that the exposure of cultured cells to 0.03mM
chloroquine resulted in lysosomal pH increases within 6 minutes of exposure.
Furthermore, their results showed that the chronic administration of chloroquine is not
associated with alkalinization of hepatocyte lysosomes. Tietz and coworkers (1990) have
also shown that intraperitoneal administration of chloroquine to rats causes an increase in
the pH of hepatocyte lysosomes 1 hour after administration with a return to baseline pH
values by 3 hours; whereas continued administration of chloroquine for up to 12 days was
unaccompanied by ftirther changes in hepatocyte lysosomal pH.
(e) Vacuolization
Chloroquine has been shown to produce swelling of lysosomes which results in
vacuolization; an indication of the early stages of necrosis in cells. The activity of an
energy-dependent proton pump helps to maintain a low intralysosomal pH (Ohkuma and
Poole, 1978). With the exposure of chloroquine to the hepatocyte, the neutral species
diffuses into the lysosome. In the amine-filled lysosome, proton-pumping proceeds at a
high rate for several hours but the entering protons are now immediately trapped by
reaction with the amine drug. The accumulation of chloroquine is accompanied by an
osmotic influx of water, resulting in an energy-dependent, visible swelling of the lysosome.
The swelling of the lysosome has been found to give a seven-fold volume increase
within an hour (Seglen and Rieth, 1976). Occassionally, the vacuoles contain recognizable
cytoplasmic organelles such as mitochondria (Crabb, 1980). Phagocytosis, the process
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whereby a cell engulfs extraneous materials, was shown to be inhibited in IgG coated sheep
red blood cells by prophylactic doses of chloroquine (600 mg/week for 6 weeks in man)
(Osorio et al.,1992). The resultant elevated pH (ie., base action) caused major alterations
in the intracellular trafficking and degradation of macromolecules, affecting receptor-
mediated endocytosis, intra-lysosomal digestion, endocytosis and the biosynthesis of
secretory proteins (Seglen and Gordon, 1979).
(f) Phospholipidosis
It has been established that cationic amphophilic compounds (CAC) such as
chloroquine increase the phospholipid content of the liver (Lullmann et al., 1978).
Yamamoto et al. (1976) showed that large doses of chloroquine given to experimental
animals for 5 to 7 days resulted in the accumulation of phospholipids in the liver, spleen,
muscle and other tissue, which appeared as intracellular multilamellar bodies in the cell
cytoplasm. The same occurred when lower doses of the drug were used for longer periods.
In the rat liver, another study showed that after 7 days of chloroquine treatment the
liver phospholipid content increased by 50% (Matsuzawa et al., 1980). Matsuzawa and
Hostetler (1980) have stated that the multilamellar bodies are the principal intracellular sites
of accumulation of chloroquine. They also indicate that two factors that result in the
experimental lipidosis are the increased delivery ofphospholipid to lysosomes and decreased
lysosomal catabolism of phospholipid. The lysosomal fraction was found to contain the
excess phospholipids with chloroquine. This suggests that phospholipase present here may
have been inhibited by chloroquine and this would ultimately have led to drug-induced
lipidosis. The multilamellar structures presented in the above instances contained acid
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phosphatase, a lysosomal enzyme marker.
In the event ofchloroquine-induced phospholipidosis, chloroquine forms complexes
with polar lipids such as phosphatidylserine by hydrophobic and electrostatic forces.
Reduction of their negatively charged form protects the lipid-drug complex from enzymatic
attack by phospholipases A and C (PLA and PLC). The complex accumulates and results
in a gradient of polar lipids within the lysosome. As soon as the concentration of the polar
lipids has attained a certain level, they form crystalloid structures with limiting membrane,
within the homogenous lysosomal matrix. These crystalloid bodies grow with time, still
possessing their limiting membrane and acid phosphatase activity (Drenckhahn et al., 1976).
Upon further exposure or continued treatment the inclusions or multilamellar bodies lose
their limiting membrane and cytochemically demonstrable activity of acid phosphatase.
This leads to the further accumulation of lipids within the lysosomes and may result in a
sometimes reversible lipid storage problem. Studies have shown that in this manner
chloroquine causes skin and phospholipid storage disorders in man (Leli and Hauser, 1987).
Madin-Darby canine kidney (MDCK) cells grown in 0.03 mM chloroquine showed
a 40% increase in their phospholipid content (Hostetler and Richman, 1982). In proposing
a mechanism of action for the drug chloroquine, Hostetler and Richman, 1982 suggested
that it must inhibit lysosomal phospholipase activity. The inhibition may occur either
directly as shown by in vitro studies with phospholipase (Pappu et al., 1983), or indirectly
by elevation of the intralysosomal pH. The appearance of multilamellar bodies mentioned
earlier appears also to be a toxic side effect.
Hostetler et al., 1985, also reported the increase of phospholipid content of
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hepatocytes of up to 70% 12 hours after chloroquine exposure. However, this increase in
liver phospholipid was not found to coincide with the times at which the pH of hepatic
lysosomes was alkaline due to the presence of the drug but rather when the pH had returned
to normal (Tietz et al., 1990). Phospholipid accumulation also occured at time points as
late as 10-12 days after chloroquine exposure. Although a relationship exists between the
induction of phospholipids and the increase in the pH of rat hepatocyte lysosomes,
chloroquine may be responsible for only initiating this response which may not necessarily
be pH-dependent.
In lysosomes, phospholipases are important in the turnover of incoming
phospholipids which may originate from lipoproteins (Matsuzawa et al., 1980; Lullmann
et al., 1978). Intracellular phospholipases are required in; (a) phosphoglyceride deacylation-
reacylation reactions referred to as Land’s cycle - which characterizes the ongoing dynamic
turnover of phospholipid acyl chains in intracellular membranes; and (b) generation of
prostaglandin precursors from the SN-2 position of phosphoglycerides.
Phospholipase A, and A2 activities have been reported in the plasma membrane,
Golgi, mitochondria and other cytosol components. Phospholipase A, is the major
phospholipase of liver lysosomes and does not require calcium ion for activity.
Phospholipase A2 plays an important regulatory role in the release of arachidonic acid from
the SN-2 position. Both are glycoproteins vvdth optimum pH of 4.0 and 8.4, respectively.
Another phospholipase, PLC, present in liver lysosomes, is specific for the
hydrolysis of phosphatidylinositol (PI) and it’s derivatives. It appears to be involved with
several cellular regulatory functions including Pi’s response to various stimuli, which
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include hormonal and neural stimuli. Chloroquine has been demonstrated to inhibit PLA
and PLC (Kodavante & Mehendale H.M., 1986) and phospholipid methylation.
Another possible mechanism was put forward by Lullman et al. (1978) to explain
the chloroquine-induced lysosomal phospholipid storage problem, this was the lysosomal
depletion of acid phospholipase. Chloroquine has been shown to cause cultured fibroblasts
to secrete lysosomal acid hydrolases into medium, resulting in decreased secretion of acid
hydrolases by intracellular fibroblasts. However, acid phosphatase A levels in liver were
found to be increased by chloroquine treatment, essentially ruling out cellular depletion of
lysosomal phospholipase in the pathogenesis of the disorder (Reasor & Hostetler et al,
1984).
In an experiment to show the extent of intralysosomal concentrations of
chloroquine and to properly evaluate the significance of in vitro inhibition data,
Matsuzawa & Hostetler (1980) used free-flow electrophoresis to isolate lysosomes and
determine their water space with ^H20 and [''*C]sucrose and chloroquine concentration by
fluorescence. The results demonstrated that an intralysosomal chloroquine concentration
of 6.3 mM was reached in liver only 12 h after a single chloroquine dose. The chloroquine
concentration rose steadily to 74 mM after 3 days of treatment of rats injected with the drug
(100 mg/kg) and the increase was accompanied by nearly a four-fold increase in lysosomal
phospholipid. The intralysosomal levels of 3 to 6 mM chloroquine (Hostetler, 1980;
Hostetler et al.,1985) attained were sufficient to account for significant inhibition of acid
phospholipase A, which was the 50% inhibition concentration (IC50). Although chloroquine
is well known for it’s ability to raise the intralysosomal pH (Ohkuma «& Poole, 1978;
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Hollemans et al., 1981) results from other studies show that an increase in pH of
hepatocyte lysosomes does not play a major role in chloroquine-induced phospholipidosis
(Tietz et al.,1990; Ohkuma & Poole, 1978).
Reports indicate that phosphatidylserine (PS) enhances dextran or antigen-induced
histamine release in the presence of Ca^"^ in a dose-dependent manner (Hawthorne, 1976).
Due to chloroquine’s bivalent nature, themolecule possesses a high affinity for negatively
charged polar lipids, such as PS and therefore binds to it (Lullmann &Wehling, 1979). This
may have some inhibitory effect on histamine release and ultimately inflammation in body
tissues. Phosphatidylinositol (PI) has been shown to be the source of arachidonic acid
required for PGE2 synthesis in mouse pancreas (Marshall et al.,1987). PI may also have a
possible role in cell growth and division. Inositol in mammalian cells is synthesized from
glucose, and is required as a viteimin for growth and division. PI is involved with the
activation of muscarine or a-adrenergic receptors on the cell surface and other receptors
that use Ca^^ as a secondary messenger.
Chloroquine alters the membrane conformation and phospholipid content by
redirecting the incorporation of radioactive precursors such as phosphate (^^ P) from neutral
lipids such as PC and PE, to acidic ones such as PI and PS. Chloroquine affects
phospholipid metabolism in different cell types. Its effect depends on the type of cell
system or tissue, species, duration of drug exposure and dose level used (Kodavanti and
Mehendale, 1990). When isolated rat mast cells (IRMC) were exposed to chloroquine and
labeled with P, Pecivova et al. (1994) showed that the turnover of PI and PS increased
while PC, PE and PA were decreased.
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2. Immunologic Effects
Chloroquine is also known as an anti-inflammatory agent. It produces this effect via
the immunological reactions involving TNF and PGE produced by leukocytes.
Tumor necrosis factor (TNF-a) is a 17 kD polypeptide, a cytokine mainly produced
by activated macrophages (monocytes) (Aggrawal et al., 1985). It was discovered upon
observing that the serum from mice injected with Bacillus Calmette Guerin (BCG) or
Lipopolysaccharide (EPS) induced tumor necrosis in tumor-bearing mice (Aggrawal et al.,
1985). It is an important mediator of the well-known in vivo effects of EPS such as tumor
hemorrhagic necrosis, fever, shock and activation ofneutrophils and eosinophils, as well as
endothelial cells which display procoagulant activity. It regulates the production of
antibodies by B-cells and stimulates cytotoxic T-cells, interleukin-6, colony stimulating
factors (CSF), prostaglandins (PGE), platelet-activating factor (PAF) and collagenases
(Vilcek& Eee, 1991). In combination with other cytokines, TNF-a is involved in several
autoimmune diseases and even in the pathogenesis of arteriosclerosis (Waage et al., 1987,
Whicher & Evans, 1990). It strongly inhibits lipoprotein lipase and adipocyte gene
expression. TNF-a displays anti-tumoral and growth regulatory activities in that it shows
a selective toxicity for tumor and virus-infected cells.
Eymphokines or interleukins (IE) are proteins secreted by isolated cells (eg.
macrophages) which mediate the interaction between immune and inflammatory cells.
They are capable ofpromoting cell growth, differentiation and functional activation. There
are several interleukins each with a unique biological activity, although some have
overlapping functions (Zubay, 1993). Macrophages produce lEl and IE6, whereas T cells
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produce IL2 to IL6 and bone marrow stromal cells produce IL7. ILl and IL6 play an
important role in immune function. They also stimulate some inflammatory eell types and
induce fever. IL2 is a potent proliferative signal for T cells. IL4 to IL6 serve to enhance
B-cell proliferation and antibody production (Zubay, 1993).
TNF-a and IL-6 production were selectively suppressed in a dose-dependent fashion
when maerophages were treated with chloroquine using concentrations 1.0, 0.5, 0.25,
0.13 mM for 2 hrs (Ertel et al, 1990; Pieot et al.,1993). Results showed that CQ inhibited
TNF and IL6 production at all four concentrations between 100% and 72%. Chloroquine
was postulated to act on TNF-a secretion by disruption of the iron homeostasis (Picot et al.,
1993). IL-1 seeretion was also shown to be inhibited by chloroquine at concentrations of
1.0 mM only, along with the presentation of antigens by accessory cells (Ertel et al., 1990).
Chloroquine depresses mitogen responsiveness and natural killer cell cytotoxieity
and displays anti-inflammatory properties (Krogstad et al.,1978; Ertel et al.,1990).
Chloroquine has an inhibitory effeet on transcription as demonstrated by Ertel et al.,
(1990) and Zhu et al., (1993). Chloroquine was shown to inhibit macrophage TNF gene
transcription with the result that TNF protein production was decreased. Zhu et al, 1993,
in their conclusion suggested that since chloroquine had the ability to inhibit macrophage
TNF-a transcription, it may serve as a promising agent in the treatment of conditions
associated with elevated TNF production, such as the inflammatory reaetion. Chelating
iron suppressed the inhibitory effect of chloroquine on TNF secretion, indicating a role for
iron metabolism in TNF inhibititon (Picot et al., 1993).
Prostaglandins and thromboxanes are related compounds biosynthesized from C20
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polyunsaturated fatty acids, primarily arachidonic acid. These eicosanoids serve as local
hormones that mediate tissue inflammation by binding to receptors on the cell surface. This
binding results in interaction with a GTP binding protein that alters the synthesis ofa second
messenger such as cAMP. The release of prostaglandin Ej (PGEj) has been shown by Ertel
et al. (1990) to be inhibited by chloroquine. PGEj is involved in the cAMP-dependent
signal pathway for marcrophage TNF production. Thus, chloroquine exerts it's regulatory
effect on TNF-a gene expression in macrophages by inhibiting both TNF and PGE release
in murine and Kupffer cells. Zhu et al. (1993) suggested that this is the mechanism by
which chloroquine produces it's anti-inflammatory effects in the immunological and
pathophysiological events associated with rheumatoid arthritis or haemorrhage.
3. Molecular Effects
Allison et al. (1965) have shown that chloroquine interacts with double-stranded
DNA stabilizing the helix. Ciak and Hahn (1965) have also indicated that chloroquine
inhibits DNA and RNA synthesis as well as growth in susceptible bacteria. More recently,
in malaria parasites (both chloroquine-sensitive and the chloroquine-resistant strains) two
labelled proteins with apparent molecular masses of 42 and 33 kDa were found to be the
macromolecular targets of chloroquine action (Foley et al., 1993). Using various analogs
of chloroquine, they established that the B-ring is necessary for optimal activity and that
substituents at the C-4 position varied the effectiveness of the inhibition, but no clear
localization was obtained. Stollar and Levine (1963) noted that the maximum number of
drug molecules bound per molecule of DNA corresponded to a ratio of one drug molecule
to each five nucleotides. These findings suggest that a specific base is involved in the
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binding; possibly guanine or cytosine, each of which constitute one-fifth of the total
number of bases in the calf thymus DNA used. However, no mechanism of
pharmacological action had yet been established. Stollar and Levine (1963) concluded that
chloroquine prevents the proliferation of immunologically competent cells by binding to
DNA. It has also been observed that some of DNA’s biological properties are markedly
altered by interactionwith chloroquine and that such complex formation can inhibit enzymic
depolymerization of DNA (Kumick & Radcliffe, 1962), reduce it’s bacterial transforming
ability (Stollar and Levine, 1963) and interfere with its function as a primer for the DNA-
dependent, DNA and RNA polymerase reaction (Cohen and Yielding, 1964). All DNA and
RNA polymerases are inhibited by the drug to about the same extent. The binding of
chloroquine to DNA is required for DNA’s biological activity to be altered. For example,
chloroquine has been shown to inhibit the complement-fixation reaction of lupus
erythrematosus serum by binding to the denatured DNA (Stollar and Levine, 1963). Also
studies with four different quinolines, analogs of chloroquine, supported the concept that
the inhibition of DNA synthesis reflected a binding to DNA (Cohen and Yielding, 1964).
Stollar and Levine (1963) showed that addition of chloroquine to bacterial-
transforming DNA during transformation reduced the number of transformants. Cohen and
Yielding (1964) also noted that inhibition of DNA polymerases by chloroquine differed
from that caused by nucleotides. Chloroquine has been shown to inhibit the incorporation
of P labeled phosphate into both RNA and DNA of Plasmodium gallinaceum
(Schellenberg and Coatney, 1961). Clearly, the ability of chloroquine to affect the
functioning ofDNA in biological systems implicates it as a possible genotoxic agent and
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a further study of its role in other DNA-dependent cellular processes such as cell cycling,
enzyme synthesis, carcinogenic adduct formation and micronucleus formation is required.
4. Clinical Toxicty
The toxicity of chloroquine seems to be related to total dosage at a specific time and
not to the accumulation of the drug in the body as a result of routine intake over a long time
(McCallister et al., 1987; Morrow et al.,1989). Keratopathy, a drug-induced lipidemia, has
been associated with chloroquine use (McCallister et al., 1987). Chloroquine phosphate and
its primary derivative, hydroxychloroquine sulfate, are known to produce ocular damage
in a dose-related fashion (McCallister et al., 1987). These investigators have noted that,
clinically, some observable complications of keratopathy include comeal deposits, loss of
pigmentation of the lashes and loss of visual acuity associated with pigment epithelial
damage. Once visible changes have occured in the retina, visual loss is irreversible and can
be progressive in spite of cessation of therapy. The earliest clinically detectable signs of
retinal damage appear to occur relatively late in the course of toxic damage to the retina.
Findings from histopathological studies obtained from postmortem human material
and non-human primates (Rosenthal et al., 1978) indicate that damage to the retina occurs
at much lower doses than the daily administered dose of 250 mg chloroquine given to
humans (Ramsey et al., 1972). Long before observable changes are detectable, membranous
cytoplasmic bodies appear in the cell bodies in ganglion cells. Degenerative changes occur
in the outer segments of cones prior to the development ofdepigmentation and loss ofapical
villous processes by pigment epithelial cells. The late stages of retinal damage are
characterized by disruption of the functional contact between pigment epithelial cells and
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the outer segments of cones. Other notable toxic effects include cardiotoxicity (McCallister
et al., 1987; Essien and Ette,1986) and neurologic effects (Adamolekan, 1993). The
therapeutic use of chloroquine has resulted in cases of death (Nelson and Conlin, 1950;
Sanghvi and Mathur, 1965). The fatalities have been attributed to chloroquine’s
cardiodepressant effects on the cardiovascular system (Sanghvi & Mathur, 1965), perhaps
a result of the alteration of the mitochondrial cell membrane, and the disruption of
associated calcium binding. In acute chloroquine poisoning, where blood levels of the drug
were greater than 10 nmol/kg, risk of death from apnoea and cardiac arrhythmia within a
few hours of ingestion were apparent (Siboni et al., 1990). Effective treatment involves
mechanical ventilation, infusion of blood pressure agents and large doses of diazepam
(Riou et al., 1988).
5. Cytotoxicity
In vitro studies show that when isolated murine thymocytes were exposed to
chloroquine at concentrations of 0.1 mM and 1 mM the number of living cells decreased by
30% and 50%, respectively (Ngheim et al.,1986). In the same study, the rate of DNA
synthesis was found to decrease with increasing chloroquine concentrations. Chen and
Leonard, 1984, reported that incubation ofmouse cell cultures with 0.05mM chloroquine
arrested cell growth and caused cell death after 1-3 days. However, simultaneous
incubation of chloroquine with either cholesterol or lanosterol prevented cell death and
permitted cell growth. Another study by Zamora and Beck, 1986, involving the treatment
of human T-cell lymphoblasts with chloroquine (CQ) showed that an in vitro concentration
of0.05 mM CQ was relatively non-inhibitory to cell growth in this cell line. However, the
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effect of the combined treatment of chloroquine (0.05 mM) and vinblastine (0.1 nM) was
much greater than when either agent was used separately. This combined exposure resulted
in a 9.5-fold decrease in cell number compared to the control. There were few or no cells
left in the flasks of the CQ + VLB or the VLB(5 nM) only-treated cultures after a 48 hour
exposure at these concentrations. For a 24 hour exposure, the relatively noncytotoxic
concentrations of VLB (0.1 nM) and CQ (0.05 mM) caused a decline in cell numbers
between 12 and 16 hours. This paralleled the decline in cell numbers observed when these
cells were incubated with a known cytotoxic concentration of 0.05 mM VLB only. Using
flow cytometric analysis, Zamora and Beck, 1986, showed that the decrease was
accompanied by an increase in the cells in the G2+M phase of the cell cycle as well as
increases in the mitotic index. It was observed that chloroquine itselfhad little effect on the
cell number, cell cycle distribution, ormitotic index at 0.05 mM. It was concluded that the
cytotoxicity of VLB was potentiated by chloroquine.
Cell morphology was also examined by electron microscopy. Both the
drug-resistant and drug-sensitive cell lines revealed vacuoles, but there appeared to be more
in the former. However, after exposure to VLB (0.1 nM), CQ (0.05 mM), or VLB (0.1
nM) and CQ (0.05mM) it was found that the cytoplasmic vacuoles increased in numbers
with the combined treatment that was greater than those of either drug alone.
Histologic staining of the treated cells for acid phosphatase that appeared to be
associated with many of the vacuoles showed less intense staining for the highly toxic
combination of the two drugs. This differed from the intense staining observed for the
lysosomal enzyme at the perivacuolar areas with cells treated with the noncytotoxic doses
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of both drugs individually. Most likely, this was a consequence of cell damage
(cytotoxicity) and leakage of the enzyme from the vacuoles (Rome et al.,1979) resulting
from the combined cytotoxic effects of the two drugs. Treated cells did not stain for lipid
in spite of the increased vacuole formation.
In another study, Cameron (1986), observed that prednisolone-induced stabilization
of lysosomal membrane was associated with a decrease in cytotoxicity of neutrophils,
whereas chloroquine- and hydrocortisone-induced stabilization of the lysosomal membrane
was not associated with a decrease in cytotoxicity (Wiessman, 1965). Pretreatment of
neutrophils with O.OSmM prednisolone as compared to similar treatment using chloroquine
and hydrocortisone was unable to suppress neutrophil cytotoxicity.
In a report by Morrow et al., 1989, chloroquine was studied as a hyperthermia
potentiator. It was found that increasing length of exposure ofmelanoma cells (for 30-min
intervals from 30 to 180 min) to 0.05 mM CQ increased cytotoxicity at both 37°C and
41‘’C. For each interval studied, treatment at 41°C significantly decreased colony formation
compared to treatment at 37“C. A cell kill of 100% was achieved at 180 min at 41°C
treatment compared to 80% cell kill at 37°C.When the cells were exposed to increasing
concentrations of the chemical ranging from 0.05 mM to 0.1 mM, a dose- dependent
cytotoxicity was shown by a decreasing colony count at both 37° and 41° C. The
investigators, concluded that chloroquine was an effective potentiator of hyperthermia.
Quarless, 1988, reported that a low dose of lOpM of the antitumor drug
cis-diamminedichloroplatinum II (cDDp), which was previously found to be noncytotoxic
to Hela S3 cells in culture (Roberts and Fraval, 1978), was greatly enhanced in its
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cytotoxicity by treating cells with 200|aM chloroquine immediately after exposure to the
platinum drug. In another study, Winstanley et al.,1990, showed that after 16 hours
ineubation chloroquine caused a significant dose-dependent cell death in mononuclear
leucocytes over the range of concentrations 1 to lOOpM. However, chloroquine presented
itself as the least toxic of the 3 other compounds (amodiaquine, quinoneimine and
desethylamodiaquine) being investigated in the study.
6. Cell Death
There has been recent interest in the homeostatic control between cell proliferation
and eell death. The two well-known modes of cell death are apoptosis and necrosis.
Apoptosis is a mechanism of cell death that usually occurs under physiological
conditions (Wyllie, 1981). It is a non-inflammatory controlled physiological process
involving cellular shrinkage, marked condensation and margination of chromatin along the
nuclear margin, an increase in the nuclear-lobes per cell which appear as densely stained in
cells. The activation of an endogenous Ca^^, Mg^"^-dependent endonuclease that degrades
the nuclear DNA in most eases is a well known biochemical feature. This results in the
formation of nuclear and cellular fragmentation and ultimately the formation of apoptotic
bodies (Kerretal., 1972). Collins (1972) described a morphologically typical apoptosis
in Burkitts lymphoma cell line without the production of a nucleosomal ladder. Such data
suggests the importance of using more than one criterion for determining the mode of cell
death (Kerr et al., 1992). Apoptotic death has been shown to occur during tissue
development and cell turnover, during metamorphosis and following deprivation of growth
factors (Wyllie,1981; Bursch et al., 1990). The process is said to take 3 hours to complete.
30
Necrosis is a mode of cell death that occurs after non-physiological insults such as
exposure to hypoxia or toxins, and may be the form of death that occurs in many cell types
under pathological situations (Wyllie, 1981). It is characterized by cells and organelles (eg.
mitochondria and endoplasmic reticulum), showing a progressive swelling and cellular
disorganization which culminates in lysis (Wyllie, 1981; Clark, 1990, Kerr et al., 1972).
Chloroquine may use either or both of the above modes of cell death during the
promotion of it’s toxicity.
G. Summary
Chloroquine, a 4-aminoquinoline, is a widely used antimicrobial and anti¬
inflammatory compound. This cationic amphophilic amine typically accumulates in acid
vesicles of cells such as fibroblasts, macrophages, thymocytes, hepatocytes, white blood
cells (lymphocytes), melanin-containing cells of the eyes and skin, epidermal cells and the
ganglion eells of the nervous system. In these vesicles it reversibly increases the pH of the
normally acidic intracellular vacuoles by becoming protonated and taking on a membrane
impermeant form within the acidic compartment. This results in changes in vesicular
transport (endocytosis, exocytosis and receptor recycling) and enzymatic activity within the
lysosome.
Chloroquine has been shown as a result of this, to disrupt amino aeid metabolism,
glycolysis, and lipid metabolism, as well as to induce phosopholipidosis and other lipid
storage problems. Chloroquine is known also to bind to DNA resulting in the inhibition of
DNA and RNA synthesis. Some clinical effects of chloroquine include ocular damage,
chloroquine-indueed lipidemia, cardiotoxicity, neurotoxicity, nephrotoxicity and teratogenic
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defects. Cardiotoxicity is believed to result from the alteration of mitochondrial membranes
of the muscular cells of the heart that in turn inhibit calcium binding and energy
production as a result of disruption of the mitochondrial energy system.
H. Rationale for the Study
Chloroquine is still the drug of choice in the treatment of some antimicrobial and
inflammatory conditions. Consequently, it is widely used in both malaria endemic regions
and by individuals with allergies. Much is known about chloroquine’s cellular and
biochemical effects both in vivo and in vitro. However, the effects ofchloroquine on DNA-
induced biochemical and molecular changes in the host cells are not clear. There still
remains the need to relate these dose-effect relationships in vitro to the toxic action of
chloroquine in vivo. Our interest in chloroquine is to examine the biological and molecular
effects of the compound on lymphocytes under in vitro conditions to increase our
understanding of the mode of action ofchloroquine and to assess risk to the host during and
after therapy.
For this study the AHH-1 human B-lymphoblastoid cell line was used. It was
chosen because lymphocytes are noted to be particularly sensitive to chloroquine’s effects.
Chloroquine is metabolized by the cytochrome P450 enzymes (notably CYP3A and
CYP2D6, among others) to its two major pharmacologically active metabolites,
desethylchloroquine and bisdesethylchloroquine. It was beneficial to have a cell line that
was metabolically competent and grew well in culture. The AHH-1 cell line also has the
advantage of having metabolic competence. It has been genetically engineered to stably
express native human cytochrome P450 and microsomal epoxide hydrolase as fimctional
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proteins which could serve as markers for an assessment of cytotoxicity and metabolite
production. It grows rapidly in suspension culture and can also be used to measure the







AHH-1 cells were seeded at a density of 5 x 10^ cells/ml in supplemented
RPMI-1640 (RPMI-1640 media, 200 mM glutamine, 100 mg/ml penicillin, 100 U/ml
streptomycin, 10% fetal bovine serum, (Atlanta Biologicals, Atlanta, GA.)) at 37“C in a
humidified atmosphere of 95% air / 5% CO2 and cultured for 7 days, with media changes
every 72 hours.
2. Cryopreservation
Cells were centrifuged at 1000 rpm for 5 -10 min. Supemate was removed and cells
resuspended in freezing media (2% fetal bovine serum, 100 mg/ml L-glutamine, RPMI-
1640, Atlanta Biologicals, Atlanta, GA.) and transferred into plastic 1.8 ml cryovials
(Nalgene Co., Rochester, NY), frozen at - 70 °C for 24 h, then transferred to liquid nitrogen
for storage and preservation.
3. Chemicals
Chloroquine disulfate, propidium iodide (PI), flourescein diacetate (FDA),
cytochalasin-B, Rnase A, Giemsa, nicotinamide adenine dinucleotide (NADH), sodium
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pyruvate, and triton - XlOO were purchased from Sigma Chemical Co., St Louis, MO.
4. Equipment
Flow cytometric analysis was done using a Becton and Dickenson FACsort (Model
660) interfaced with a Macintosh Quadra 650 computer; spectrophotometric analysis was
done using a Beckman Du-6 spectrophotometer. A Beckman centrifuge (Model GS-6R)
was used to centrifuge cells and cell counts were estimated with a hemocytometer. A Nikon
Labophot-2 light microscope was used for scoring cells and electron microscopic analysis
was done using a Phillips transmission electron microscope.
B. Methods
1. Cell Culture
Cells were seeded at a density of 3.5 - 5 x 10^ cells/ml in SRPMI, then exposed to
chloroquine at variable concentrations (0, 0.05, 0.15, 0.2, 0.3, 0.4, 0.45, 0.6 and 0.8 mM)
for 1 to 168 hours. The chemical was then removed at the required time, by centrifugation
and aspiration of the supemate. Cells were washed in warm supplemented 1 X PBS
solution (Cellgro, VA), resuspended in growth medium (SRPMI) and counted by using a
hemocytometer. AHH-1 cells were then processed, analyzed or reincubated as the specific
assay required.
2. Drug Preparation
A 20 mM stock solution of chloroquine was prepared fresh by dissolving
chloroquine disulfate (Sigma Chemical Co., St Louis, MO.) in Dulbecco’s phosphate
buffered salt solution (1 X PBS)(Cellgro, VA) and filter sterilized before removal of
required volumes.
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3. Cell Viability and Proliferation Assays
(a) MTT Assay
The MTT method of monitoring in vitro eytotoxieity determines the number of
viable cells by measuring the mass of cells via the mitochondrial dehydrogenase activity.
Using an MTT{3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide} in vitro kit
(Sigma Chemical Co., St. Louis, MO.), treated cells were assessed for viability by reacting
this substrate with the mitoehondrial dehydrogenase enzyme present in the cells. The
product, formazan crystals, were dissolved in isopropanol, and its absorbance measured
spectrophotometrically at 570nm. The prescribed method was followed with minor
modifications.
Briefly, an aliquot of 1 x 10^ cells was removed from each treated cell suspension
culture at 6 hours and 24 hours, pelleted and made up to 2 ml with SRPMI. To this was
added 10% MTT to give the reaction mixture a volume of 2.25 ml with SRPMI. From the
reactionmixture, 0.1 ml was placed in each well of a 96-well microtitre plate and incubated
for 2 hours at 37®C, in an atmosphere of 5% CO2. The microtitre plate was removed and
0.1 ml of a solubilization agent (10% Triton X-100, 0.1 N HCl-Isopropanol 1/24 v/v) was
added to each well. The absorbance for the amount of dissolved formazan crystals
produced from the substrate (MTT) reacting with mitochondrial dehydrogenase was read at
570 nm using a microtitre plate reader. This absorbance was used as an index of the




The acid phosphatase method ofmonitoring in vitro cytotoxicity determines the
number of viable cells by measuring the mass of cells via cell-membrane associated acid
phosphatase. Briefly, aliquots of 1 x 10^ cells were removed from the cell suspension,
centrifuged and supemate removed. Cells were then washed in warm supplemented 1 X
PBS and resuspended in 1 ml fresh media. From this volume 0.5 ml of cell suspension was
removed and placed in a 2 ml capped plastic tube. To this was added 0.625 ml of fresh
media and 0.125 ml ofp-nitrophenyl phosphate. The tube was capped and shaken and 0.1ml
was placed into each well of a 96-well microtitre plate for each dose. Plates were
incubated at 37'^C in an atmosphere of 5% CO2 for 2 h. Absorbances were
spectrophotometrically measured at 405 nm using a BioRad Model 450 microplate reader.
Enzyme activities were expressed in Absorbance Units / Cell No.
4. Apoptosis
The treated and the untreated cells were seeded at a density of 3.5 x 10^ cells/ml in
SRPMI for 0, 24,48, 72, 96,120, 144 and 168 hours at concentrations of chloroquine : 0,
0.1, 0.2 and 0.3 mM, continuously with media changes occuring at 72 hr intervals with the
drug included in the treatment flasks. In a second experiment to determine short term
toxicity at a high dose (acute exposure ), the cells were exposed to chloroquine at 0.6 mM
for 24 hrs only, then the drug was removed from the cells by centrifugation and the old
supemate aspirated off At the specified times, cultures were harvested and stained for flow
cytometric analysis to determine apoptosis using themethod described by Pavlik et al.(l 984)
and Ross et al. (1989). Briefly, aliquots of cells (the required volume for 1x10^ cells per
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dose point, was established quantitatively at the first sampling time, only and maintained for
all the subseqeunt sampling times) were removed at the specified time points during
treatment. The chemical was removed by centrifuging the cells at 700 rpm for 10 min,
aspirating off supemate and washing twice in supplemented 1 X PBS, pH 7.4. The
harvested cells were pelleted by centrifugation, supemate removed and cells resuspended
in 5.0 ml of SRPMI with 50 pi of 1.0 pg/ml propidium iodide staining solution and 25 pi
of 1 pg/ml fluorescein diacetate staining solution. To allow for staining, cells were
incubated at 37“C for 10 min. Excess stain was removed by centrifugation and the
supernatant aspirated. The stained cells were then resuspended in 1 X PBS, pH 7.4 and
maintained under an aluminium foil light shield on ice until FCM analysis.
For the acute exposure study of24 hours, the remaining cells were cultured in fresh
SRPMI at a density of 3.5 x 10^ cells/ml and aliquots of 1 x 10^ cells per dose removed at
intervals for FCM analysis.
5. Cell Cycle Progression
Aliqouts ofcells (5x10® cells) were harvested at the 24,48 and 72 hour time points.
The chemical was removed from cells as described above and cells processed according to
the method of Dolbeare et al., 1983. Briefly, cells were pelleted by centrifugation, the
supemate aspirated and cells resuspended in 15 ml SRPMI with 50 pi of 1 mg/ml
bromodeoxyuridine (BrdU). The cells were maintained under an aluminium foil light shield
and incubated for 1 hour at 37°C. To remove excess stain cells were pelleted by
centrifuging for 10 min at 700 rpm, the supemate was then discarded. The cells were
gently resuspended in 10 ml of 1 X PBS, pH 7.4 supplemented with 1% bovine serum
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albumin. After pelleting, supematewas removed by aspiration and the cells resuspended
in 0.5 ml normal saline and placed on ice for 10 min. Thereafter, 6 ml of 70 % cold ethanol
was added to each tube, capped and kept at -20°C until analyzed by flow cytometry within
seven days, within which time cells remained intact.
The frozen samples were centrifuged at 700 rpm for 10 min and the supemate
aspirated off. The pellet was resuspended in 5 ml HCl / Triton X-100 and incubated at room
temperature for 30 min in the dark. The sample was pelleted by centrifugation, supemate
removed and cells resuspended in 5 ml of 0.1 M sodium borate, pH 8.5 for 10 min at room
temperature. After centrifugation the supemate was removed by aspiration and the cell
pellet resuspended in 1 ml 1 X PBS and counted. An aliquot of 1 x 10® cells per flask was
transferred to separate tubes. The supemate was removed after centrifugation and 50 p.1 of
1 X PBS/1% BSA/0.5% Tween 20 and 20 pi of anti-BrdU was mixed with the cells and
incubated for 30 min at room temperature in the dark. Cells were resuspended in 4 ml of
1 X PBS and centrifuged, the supemate was removed by aspiration. To the cells was added
1 ml of 5 pg/ml propidium iodide and mixed before incubating on ice in the dark for
30 min. The cells were centrifuged, supemate aspirated and the pellet resuspended in 0.5
ml 1 X PBS. Tubes containing samples were placed on ice and shielded from light with
aluminium foil imtil ready.
Another method was used to analyze the cells for cell cycle progression. The second
method was necessary because some of the reagents in the first method were not available
when the experiment was repeated at a different location. An aliquot of 1 x 10® cells was
removed from the control and treated flasks and placed in 15 ml plastic propylene capped
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tubes. Cells were washed in 1 X PBS and after centrifuging at 1000 rpm for 5 min the
supemate was removed. Cells were then suspended gently in 1 ml cold 70% ethanol and
stored at 4 °C until analyzed 1 week later. This was to allow for the apoptosis analysis
previously mentioned to be performed on the cells immmediately they were harvested.
Before the analysis, cells were pelleted, ethanol removed and stained by
resuspending them in 0.8 ml staining solution / tube and incubated on ice in the dark for 1
hour with mixing every 15 minutes. The propidium iodide staining solution was prepared
fi-esh using 0.5 ml 1 mg/ml propidium iodide (50 pg/ml final), 1 ml 10 mg/ml Rnase A and
1 gm/1 glucose buffer. The samples were analyzed using flow cytometry.
6. Micronucleus Assay
Cell cultures were incubated at 37°C, in an atmosphere of 5% CO2 for the following
time points: 0,1, 3, 6 and 24 hours with specified doses of chloroquine. After treatment the
chemical was removed by centrifugation and the cells were washed twice with warm
supplemented 1 X PBS. The cells were resuspended in fresh SRPMI using T-25 culture
flasks and incubated for an additional 44 hours. Cytochalasin B was added to each culture
to give a final concentration of 6 pg/ml and cultures incubated continuously for a further
28 hours.
Cells were washed with warm supplemented 1 X PBS twice and resuspended in
hypotonic medium consisting of 4 parts RPMI-1640 and 1 part distilled water with 2% fetal
bovine serum (FBS). Cells were pelleted by centrifugation at 1000 rpm for 5 min. The
hypotonic medium was removed by aspiration leaving approximately 0.5ml above each
pellet. Using a glass pasteur pipette, the pellet was resuspended in the hypotonic medium
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and two drops smeared over a clean microscopic glass slide and air-dried. Prepared slides
were immersed in a (3:1) methanol: glacial acetic acid solution for 3-5 min. After air
drying, the slides were stained with 10% Giemsa for 20 min. Slides were scored
microscopically by counting the number of micronuclei associated with 500 binucleated
cells.
7. Enzyme Assays
Cultures were set up at a cell density of 5 x 10^ cells/ml for 6, 24, 48, 72 and 96
hours of incubation with chloroquine. All cultures were incubated at 37°C in a humidified
atmosphere of 5% CO2 in air. An aliquot ofapproximately 1x10^ cells was removed from
each dose at the specified times, washed and the pellet suspended in 1ml 1 X PBS
immediately after treatment with 0.1% Triton-XlOO to lyse cells. The Triton-XlOO was not
removed since it was known not to affect enzyme activity at that concentration and below.
Lactate dehydrogenase was assayed using the method previously reported by Acosta
et al (1978). Briefly, to 625 pi ofwarm O.IM PBS in a quartz cuvette was added 50 pi
sodium pyruvate, 50 pi NADH and 25 pi of the sample (supemate only or suspension with
lysed cells) and mixed. The enzyme activity was measured spectrophotometrically at
340 nm, using a Beckman 600D spectrophotometer over 4-5 min at 1 min intervals.
To determine the amount ofLDH released from the cells in culture and the amount
remaining in the cells (cellular LDH), 4 mis of cell suspension were removed from each
flask and 2 ml placed into two separate 15 ml plastic tubes. One tube was used for assay
of LDH in the supernatant only after centrifugation at 1000 rpm for 3 min to remove the
supemate from the cells and the second assayed for total LDH in the tube after lysing the
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cells first with 0.1 % Triton X-100. The lactate dehydrogenase assay was run at the time
points indicated above and the activity levels in treated cells expressed as U/ml and were
compared with that in the controls.
8. Cell Morphology
Cells at a density of 4.5 x 10^ cells/ml were exposed to chloroquine at
concentrations of 0, 0.2, 0.4, 0.6 and 0.8 mM for 6 hours and 24 hrs. The chemical was
removed at both time points by centrifugation and treated cells washed twice in warm 1 X
PBS. The pellet was resuspended in 4% glutaraldehyde in 0.1 M phosphate buffer, pH 7.3
at 4°C and samples kept on ice to be processed for electron microscopic analysis.
Treated cells were processed for electron microscopy using standard procedures
(Kushida,1962; Lewis et al., 1974; Reid, 1974). Briefly, cells were fixed in 4%
glutaraldehyde in 0.1 M phosphate buffer, pH 7.3 at 4°C and then rinsed in 0.2 M phosphate
buffer, pH 7.3 at 22°C. The suspensions were centrifuged at 2600 rpm for 15 minutes
between each rinse to form a pellet which was then re-suspended. Post-fixation was in 1%
osmium tetroxide followed by a buffer rinse. The suspension was centrifuged and the
resulting pellet then placed in an agar pellet for further processing. The samples were then
dehydrated in an ascending series of alcohol rinses, cleared in 100% acetone, infiltrated in
an epoxy resin and embedded in firesh epoxy resin. Polymerization was at 45°, 60° and 85°C.
Thin sectioning was on an LKB Ultrotome III at 600-900 angstroms thickness. The
sections were placed on 150 mesh copper grids, stained with uranyl acetate and lead citrate
then viewed on a Phillips 301 transmission electron microscope at various magnifications.
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9. Statistical Analysis
Where appropriate the data were analyzed using the analysis of variance (ANOVA)





Cells were grown in SRPMI-1640 till they reached the logarithmic phase, and at the
specified times 1 ml aliquots of the cell suspension were removed and the cells counted
using a hemocytometer. The Figure 2 shows the growth kinetics of untreated AHH-1 cells
in culture for 7 days. It indicates a 2 day period where no visible growth occurs, followed
by an increased growth pattern for normal B-lymphocyte cells in culture from day 3 to day
7. The doubling time of these control cells during logarithmic growth was between 17 and
24h.
B. Cell Viability
Cell viability was tested using trypan blue dye and the cells were maintained
between 90-98% throughout the logarithmic growth period. All the subsequent experiments
were done using normal cells with >95% viability.
Figure 3 represents the growth profile of control and cells treated wnth chloroquine
continuously at the following concentrations: 0,0.2,0.4, 0.6 mM for a duration of 4 days.
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Figure 2. The growth kinetics of untreated AHH-1 lymphoblastoid cells
Celicount(x10e6)
4:^
Figure 3. The growth kinetics of untreated versus chloroquine-treated AHH-1 cells (0-0.6 mM)
Cellcounts(x10e6)
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After 24 h the growth profile of cells exposed to chloroquine showed a decline of 8%, 22%,
54% at 0.2, 0.4 and 0.6 mM chloroquine, respectively, as compared to controls. Above
0.2 mM cell growth was significantly inhibited, and cells showed signs of clumping
together.
After 32 hours ofexposure at 0.2, 0.4 and 0.6 mM, a dose-dependent decline in cell
number (30%, 45.3% and 70.9%) was observed. This trend continued after 80 hours of
exposure with a sequential loss in cell numbers (85%, 98.2% and 99.3%, respectively) when
compared to the parallel control. At 152 hours after exposure only 6.2%, 1.2 %, 1.1%,
respectively of the treated cells niunbers remained when compared to the parallel control
at that same time point.
C. MTT Assay
At 6 hr after exposure to chloroquine at the 0.2, 0.4, and 0.6 mM cell viability
decreased correspondingly (23.3%, 46.6%, 52.1%) when compared to the parallel control.
At the 24 hr time point the values obtained when compared to the parallel control were
53%, 63% and 68% for the respective concentrations of chloroquine. At 48 hr, 60.4%,
80.3% and 96.5% decrease in cell viability were observed for the 0.2, 0.4, and 0.6 mM
treatments (Table 1). The data showed a dose-dependent decrease in cell viability. These
differences were statistically significant at p<0.05, when compared to control. Figure 4
shows the percentage decline in viable cell numbers after treatment.
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Table 1. Effect of chloroquine on cell viability using mitochondrial dehydrogenase
(U/mL) activity as an index
Time Chloroquine(mM)
0 0.2 0.4 0.6
0 0.171+0.020 0.148±0.016 0.166+0.018 0.150± 0.014
(n=15) (n=15) (n=14) (n=12)
6 0.146+0.016 0.112+0.006 0.078±0.019 0.070±0.020
(n=6) (n=7) (n=4) (n=3)
24 0.219+0.014 0.103±0.008 0.082+0.006 0.071±0.008
(n=ll) (n=7) (n=8) (n=8)
48 0.376+0.019 0.149±0.005 0.074±0.005 0.013+0.007
(n=4) (n=4) (n=5) (n=8)
* P<0.05 *P<0.05 * P<0.01
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Figure 4 represents the percentage of viable cells remaining after cells were
exposed to chloroquine(mM) for 48 h compared with the control.
T iaeChrs)
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D. Acid Phosphatase Assay
At 6 hours, acid phosphatase activity decreased by 25 % at 0.2 mM and increased
by 25%, 50%, at 0.2, 0.4 and 0.6 mM treatments, respectively, when compared with the
control (p<0.05). The trends were similar at 24 h. The activity significantly increased by
50% and 125%, respectively at 0.4 and 0.6 mM, when compared to the parallel control
(p<0.05). In contrast, the 0.2 mM was similar to the control. However, at 48 hr a decline of
33% below the control value (the activity adjusted for cell numbers) occurred in all the
treatments. Figure 5 shows the effect of chloroquine on the acid phosphatase activity of
control and treated cells, it illustrates the effect of chloroquine on cell viability using acid
phosphatase as an index in AHH-1 cells in vitro.
E. Apoptosis
Determination of viable, apoptotic and necrotic cells
The effect of chloroquine on cell viability was determined by flow cytometry with
the propidium iodide/fluorescein diacetate assay. Tables 2 and 3 show the distribution of
cells gated under viable, apoptotic and necrotic cell populations after treatment ofAHH-1
cells with chloroquine at doses 0-0.6 mM. The percentages for the viable cell population
at 6 hours show a dose-dependent decrease in the viable cell populations of 11.9%, 27.3%
and 33.7%, respectively for 0, 0.2, 0.4 and 0.6 mM when compared to the control. Table 2.
The 24 hr shows a 56.8%, 90.6% and 99.2% decrease respectively, for the 0.2, 0.4, 0.6 mM
under the viable cell population. However, the apoptotic cell population at 6 h showed
increases of 17%, 7% and 0.6% respectively, for the 0.2, 0.4 and 0.6 mM, when compared
to the control. The apoptotic cell population at 24 h showed dose-dependent increases of
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Figure 5 represents the effect of chloroquine on cell viability using Acid Phosphatase
expressed as (U/Cell No.)- Points represent the ratio between the mean activity (X
± SD) of the Experimental versus the Control for each concentration and time
point.
Ratioofe dphosphataseactivi ies
Table 2. Cells gated using flow cytometry for a 6 hr chloroquine treatment
Dose(mM) Viable Cells Apoptotic cells Necrotic cells
0 83.4K6.67 10.6±0.85 4.20± 0.34
0.2 73.50±5.88 12.40±0.99 7.98± 0.64
0.4 60.65+4.85 11.35±0.91 18.82±1.51
0.6 55.32±4.43 10.66± 0.85 24.74± 1.98
^ Mean ± S.D. values (n = 3 )
Table 3. Cells gated using flow cytometry for a 24 hr chloroquine treatment
Dose(mM) Viable Cells Apoptotic cells Necrotic cells
0 89.68±7.17 3.40±0.27 5.38±0.43
0.2 38.76±3.10 22.51±1.80 32.30±2.58
0.4 8.44±0.66 53.31±4.26 33.57±2.69
0.6 0.70±0.66 64.03±5.12 32.03±2.56
“ Mean ± S.D. values (n = 3 )
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5.6-fold, 8.9-fold and 17.8-fold, respectively for the 0, 0.2, 0.4 and 0.6 mM, when
compared to the control. Table 3. The necrotic cell population at 6 h showed increases of
3.5-fold and 4.9-fold for the 0.4 and 0.6 mM when compared to the control, the 0.2 mM
remained the same. The necrotic cell population at 24 h showed increases of5-fold, 5.2-fold
and 5.4-fold respectively, for the 0.2,0.4 and 0.6 mM when compared to the control. The
summary of the data for the 24 h treatment is shown in Figure 6. Electron micrographs of
control cells (Figures 7) showed intact cell and nuclear membrane with well defined
cytoplasm and organelles with few vacuoles, whereas the treated cells (Figure 8) 24 h after
exposure appeared to have increased vacuoles (lysosomes, endosomes and phagosomes)
with electron dense cytoplasmic inclusions and showed signs of the disruption of the cell
membrane, leading to premature cell lysis with cytoplasmic contents released. The
described events were indicative of cell necrosis induced by chloroquine.
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Figure 6 shows the effect of chloroquine (mM) on the distribution of viable, apoptotic,

















Figure 7 represents electron micrographs ofuntreated AHH-1 cells. Arrows show intact
organelles(l-mitochondria, 2-rough endoplasmic reticulum, 3-nucleus,




Figure 8 represents electron micrograghs of 24 h chloroquine treated AHH-1 cells for the
concentrations : 0.3 mM and 0.6 mM. Notable differences in cell features include
(l)-increased vacuoles (size and number) with electron dense cytoplasmic
inclusions, (2)-disruption of cell membrane resulting in cell lysis with release of
cell contents into the media.
Chloroquine treated cells:
0.3 mM C0(24 h exposure) (Mag x4500)
0.6 mM CQ(2-1 h exposure) (Mag x4500)
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F. Continuous Treatment Using Low Doses ofChloroquine (0-0.3 mM)
1. Viable cells (0 to 0.3mM)
The treated cells all showed a depression in cell growth over the entire duration of
the experiment as compared to the control (Table 4). During the first 24 hrs cell viability
increased by 28.6% in the control, remained the same at 0.1 mM and 0.2 mM but decreased
by 33% at 0.3 mM (Table 5). At 48 hr, cell viability in the control increased by 36.8% but
remained the same in the 0.1 mM, where as cell viability decreased by 32% and 54% at
0.2 mM and 0.3 mM, respectively. At 72 hr, cell viability in the control was maintained,
but decreased by 6.9%, 48.9% and 64.6% at 0.1, 0.2, and 0.3mM, respectively. At 96 hr,
cell viability in the control increased by 34.7 % but decreased by 30.8%, 78.1% and 97.2%,
at 0.1, 0.2 and 0.3 mM, respectively. At 144 hr, cell viability in the control increased 3.5-
fold, but decreased by 1.8-fold, 26-fold and 202-fold at 0.1,0.2 and 0.3 mM, respectively.
After 7 days, cell viability in the control increased by 3-fold at 0.1 mM but declined by 51-
fold and 153-fold at 0.2 and 0.3 mM, respectively.
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0 45.64 42.50 45.08 38.78
24 55.96 45.86 47.08 27.49
48 60.10 44.06 35.21 27.76
72 63.36 42.32 30.10 20.25
96 69.08 37.84 35.37 11.99
144 153.55 54.24 30.65 13.29
168 140.00 56.12 25.43 13.88
Mean of triplicate counts/flask
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Table 5. Calculated viable® cell counts (xl0e6) and percentage ® of gated viable cells





0 36.30/79.58 36.60/86.01 37.83/83.92 32.26/83.20
24 46.68/83.42 39.10/85.26 38.71/82.22 21.58/78.51
48 49.78/82.83 38.04/86.34 25.83/73.37 14.72/53.04
72® 48.45/76.47 34.10/80.57 19.35/64.28 11.43/56.46
96 48.90/70.79 25.30/66.82 8.30/23.47 0.89/7.45
144 d 130.18/84.78 20.10/36.99 1.45/4.74 0.16/1.22
168 108.57/77.55 16.80/29.90 0.74/2.91 0.21/1.54
®Mean reading (n=2)
^ Added 35.4 ml to flask after counting
Cells were centrifuged and supemate removed. Cells were resuspended into fresh media.
° 20 ml fresh media was added to control flask after counting
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2. Apoptotic cells
The percentage of cells gated as apoptotic in Table 6 are considered. The expected
presentation of apoptotic cells in the control vs treated can be seen to follow a pattern. At
24 h there was a decline in the percentage of apoptotic cells in the control from 13.49% to
9.98%, a 26% decrease. The 0.1, 0.2 and 0.3 mM showed percent decreases of 11.5%
16.9 % and 8%, respectively at 24 h. However, at 48 h, although the control, 0.1 mM and
0.2 mM showed a continued decrease of 34 % 20.1% and 10 %, respectively in their
apoptotic cell populations, an increase of 28% in the 0.3 mM was observed. At 72 h, a
decrease of 18.6 % and increases of 31.5% and 62% at the control, 0.2mM and 0.3 mM,
respectively. The 0.1mM maintained its apoptotic cell population at the previous day zero
value. From 96 to 168 h post-treatment, the treated cells all showed a trend towards
increasing apoptotic cells whereas the control reached a maximum of 24% (Table 6) and
continued to decrease in the apoptotic cell population, subsequently. The 168 h time point,
showed increases of 4-fold, 5.7-fold and 6.9-fold over their initial day zero values at the
0.1, 0.2 and 0.3 mM, respectively. Table 6.
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Table 6. Calculated Apoptotic ^ cell counts (xl0e6) and percentage ® of gated apoptotic





0 6.16/13.49 4.28/10.08 5.67/12.57 5.06/13.05
24 5.58/9.98 4.09/8.92 4.92/10.44 3.31/12.05
48 2.86/8.86 3.55/8.05 4.00/11.35 5.01/18.06
72 6.96/10.98 4.27/10.08 4.97/16.53 4.27/21.10
96 16.60/24.03 7.42/19.62 11.10/31.40 4.54/37.86
144 12.73/8.29 17.13/31.59 20.44/66.70 10.10/76.30




The percent necrotic cell population at 24 hours showed an increase of 36.2%,
55.6%, 64.7%, at O.lmM, 0.2 mM and 0.3mM, respectively (Table 7). The control
maintained it’s necrotic cell population. At 48 hours a similar trend continued with the
greatest increases in necrotic cells occurring at the 0.2 and the 0.3 mM. These increases
were 79.5% and 88.7% respectively over the initial day zero. At 72 hours, increases of
1.92-fold, 2.6-fold, 6-fold and 6.8-fold at the control, 0.1, 0.2, 0.3 mM, respectively were
obtained. By 96 hours, 0.2 mM and 0.3mM had reached amaximum increase of 14.24-fold
and 17-fold, respectively. The control showed no change but O.lmM showed a 3-fold
increment when they were also compared to their initial zero values. Notice that at 144 h
cells treated with O.lmM chloroquine had reached a maximum population of necrotic cells
indicated by a 8.3-fold increase over the zero value, followed by 8.62-fold, 6.7-fold
increases at the 0.2 and 0.3 mM, respectively. The control showed an increase of less than
0.1-fold. However, at the 168 hr time point it was the control that had reached its maximum
increase in necrotic cells shown by a 2.24-fold increase over the initial value. The 0.1, 0.2,
0.3 mM showed increases of 8.3-fold, 7.5-fold, 8.02-fold, respectively. Table 7.
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Table 7. Calculated necrotic ^ cell counts (xl0e6) and percentages ^ of gated necrotic





0 2.89/6.34 1.44/3.38 1.42/3.16 1.24/3.21
24 3.46/6.18 2.43/5.30 3.35/7.31 2.50/9.09
48 4.99/8.30 2.43/5.52 5.45/15.49 0.80/28.60
72 7.72/12.19 3.75/8.87 5.62/18.66 4.44/21.93
96 3.83/5.55 5.10/13.73 5.92/45.01 6.54/54.57
144 10.73/6.99 17.04/31.43 8.35/27.23 2.84/21.38
168 19.92/14.23 15.84/28.24 6.45/25.37 1.21/8.70
“Mean reading(n=2)
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G. Short Term Treatment using a High Dose ofChloroquine
The effect of chloroquine on AHH-1 cells was studied for a high dose of 0.6 mM
for 24 h was compared to a parallel control. The control had an approximate doubling time
of23.94 h which was considered normal by the suppliers. At 24 hours, cell death of 54%
was observed at 0.6 mM. At 48 hours, cell counts had further declined by 37% at 0.6 mM.
Although a cell growth of 12.8% was observed at 72 hours after the 0.6 mM treatment,
growth in the exposed cells was inhibited. At 120 h after treatment cells produced an
inhibited growth pattern which was evidenced by the decreased doubling time of 98.3 h.
Figure 9.
1. Distribution ofCells after 24 h treatment with 0.6 mM Chloroquine
(a)Viable cells
At 24 h, the control cells produced an increase in viable cell counts. Table 8.
Consequently, the 24 h chloroquine-treated cells produced a decrease of 3.3-fold in cell
count. This trend continued at 48 to 96 hours. The control showed a maximum increase
at 144 h of 5.1-fold, this was contrasted by a 1.4-fold decrease in the 0.6 mM that showed
some cell growth and increases in cell viability, when percent values showed 76.14 % viable
in the treated cells as reflected in the cell. The trend continued at 168 h with the control
showing a 4.8-fold increase in viable cell counts and the 0.6 mM showing 82.69% viable
cells, an increase in viable cell counts.
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Figure 9 shows the growth kinetics of untreated versus 0.6 mM chloroquine treated
AHH-1 cells The first 24 hours represents treatment time after which the drug
was removed and cells resuspended in fresh media for the remainder of the test
period where counts were taken at the specified time points. Points represent the
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(Cell Count x 10e6)®
0 83.67±0.81 16.86±2.78 84.15±0.49 16.70±3.58
24 85.67±2.93 36.90±1.60 56.48±1.01 5.11±2.02
48 88.75±1.43 35.62±2.56 43.10±0.45 4.36±1.87
72 86.92±1.07 54.69±1.98 45.00±0.04 4.38±1.67
96 91.50±0.38 63.73±0.87 44.85±0.82 5.12±1.52
144 79.24±0.95 85.31±2.48 76.14±1.37 12.3010.67
168 63.34±0.31 80.38±1.65 82.69±0.62 15.4511.78
^ Table values represent mean + S.D. (n=2)
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(b)Apoptotic and Necrotic cells
After 24 hours of exposure AHH-1 cells exposed to 0.6 mM chloroquine had
apoptotic cell counts that increased by 2-fold in the control and decreased by 1.0-fold in
the 0.6 mM. At 48 hours, apoptotic cell counts had increased by 1.5-fold and 2.2-fold,
respectively in the control and 0.6mM. These trends were similar to cells in fresh media
after exposure for 72, 96 and 144 h. Finally, at 168 hours, the control and 0.6 mM showed
an increase of 3.8-fold and 1.07-fold, respectively. Table 9. In the necrotic cell population
there was an increase in the cell numbers after 24 h relative to control (95% in the treated
versus 23% in the control). At subsequent time points after drug removal (48, 72, 96, 144
and 168 h) the number of necrotic cells in the control significantly increased (p< 0.050)
relative to the treated. Table 10. The data is summarized in Figure 10.
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(Cell Count X 1066)“
0 9.80±0.69 1.98±0.48 10.36±0.33 2.05±0.69
24 9.01±0.57 3.88±0.67 20.70±0.52 1.87±1.56
48 7.68±1.32 3.08±0.87 43.55±0.25 4.41±1.75
72 4.90±0.32 3.08±0.43 37.86±0.96 3.69±2.89
96 3.82±0.13 2.66±0.79 41.45±0.49 4.73±1.54
144 4.31±0.03 4.64±0.64 18.15±0.73 2.93±1.49
168 5.97±0.36 7.58±0.58 11.73±0.27 2.19±0.85
Table values represent mean j^S.D. (n=2)
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(Cell Count x 10e6)“
0 6.54±0.02 1.32±0.78 5.30±0.21 1.05±0.01
24 3.75±0.28 1.62±1.87 22.70±0.42 2.05±0.00
48 3.64±0.12 1.46±0.68 13.30±0.90 1.35±0.02
72 4.11±0.04 2.59±1.28 16.24±0.56 1.58±0.01
96 4.69±0.28 3.27±1.60 13.50±0.45 1.54±0.01
144 16.15±0.64 17.39±2.48 5.21±0.36 0.84±0.01
168 30.58±0.65 38.80±1.65 4.14±0.41 0.77±0.02
Table values represent mean+S.D. (n=2)
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Figure 10 shows the distribution patterns for Viable, Apoptotic and Necrotic cells when
normal cells were treated with 0.6 mM chloroquine for 24 hrs and the drug was
removed and cells washed and resuspended in fresh media. These were compared
with their corresponding control. The conditions remained the same at the other
time points not shown. The histogram represents the mean ± SD(n=2).
Ti*e (hns)
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H. Cell Cycle Analysis by Flow Cytometry
The percentage of cells in the various stages of the cell cycle did not show any
significant difference between the treated and the control. Tables 11 and 12, show the data
for the cell cycle analysis ofAHH-1 cells exposed to 0.6 mM chloroquine vs the control.
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Table 11. Percentage of cells in cell cycle progression for the control
Time (hr) G1/G0(%)" G2+M(%)" S(%)‘‘
0 52.50±0.14 16.70±1.13 30.70±1.27
24 52.30±0.71 18.95±1.06 28.55±0.35
48 57.75±1.34 16.85±0.64 25.30±0.71
72 58.05±0.92 18.25±0.07 23.55±0.77
96 59.55±1.77 18.75±1.20 21.55±3.04
144 63.35±0.49 15.80±0.28 20.70±0.14
168 60.65±0.92 14.50±0.71 24.70±1.56
“ Table values represent mean + S.D.(n=3)
Table 12. Percentage of cells incell cycle progression for chloroquine-treated.cells
Time (hr) G1/G0(%)“ G2+M(%)" S(%)"
0 49.05±0.35 18.25±1.20 32.50±1.56
24 56.57±0.35 21.45±1.90 21.45±2.19
48 62.05±4.17 12.65±1.62 25.15±2.47
72 48.95±0.78 22.65±1.91 28.30±2.69
96 48.30±0.71 19.00±0.12 32.55±0.78
144 57.85±0.50 14.50±1.45 27.60±0.98
168 55.70±0.57 16.80±0.42 27.05±1.48
® Table values represent mean + S.D.(n=3)
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I. Micronucleus Assay
Table 13 represents a positive control for the micronucleus assay which shows the
mean frequencies of micronucleated lymphocytes after irradiation by a cesium source at
increasing doses. There is a dose-related increase (0 MN/500BN) for all the treatments
when comparedwith the control, wdth the highest increase (130±8.0 MN/ 500 BN) observed
at 6.0 Gy. Tables 14 and 15 represent a comparison of the effect of dose and duration of
exposure on chloroquine-treated AHH-1 cells. The cells were exposed to the drug for 1, 3,
6 and 24 hours, the drug was washed off and cells placed in fresh media. At all the
exposures and time points tested (0 to 0.8 mM), the frequency of MN was higher than the
parallel control. At 0.8 mM chloroquine treatment the 3 and 24 hr time points showed the
highest micronucleus frequencies of 3.6 % and 4.8%, respectively (Table 14 and 15). The
effect of chloroquine exposure produced a significant (p<0.0001) dose-related increase in
the frequency ofMN induction relative to the control.
73
Table 13. Mean frequency ofmicronuclei induction in AHH-1 cells exposed to
irradiation.
Dose (Gy)** N'’ No. of BN** No. ofMn** %MNBN"
0 3 500 0 0
0.5 3 500 18.0±1.0 3.6
2.0 3 500 34.7±1.2 6.9
4.0 3 500 50.0±6.0 10.0
6.0 3 500 130.0±8.0 26.0
“ Cesium source of irradiation





MNBN- No. ofmicronuclei/500 Binucleated cell
Table 14. A comparison ofMN frequencies in control versus chloroquine-treated
AHH-1 cells(l and 3 h)
Dose (mM) N No. ofBN No. ofMN MNBN No.ofMN %MNBN
0 3 500 1.0±1.0 0.3 0 0
0.2 3 500 5.0±1.0 1.0 10.0±2.0 2
0.4 3 500 6.0±1.0 1.2 6.0±1.0 1.2
0.6 3 500 10.0±1.0 2.0 10.0±2.0 2.0
0.8 3 500 ND. ND. 17.0±8.0 4.8
Harvest 1 1 3 3
Time (h)
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Table 15. A comparison ofMN frequencies in control versus chloroquine-treated
AHH-1 cells (6 and 24 h)
Dose (mM) N No. ofBN No. ofMN %MNBN No.ofMN %MNBN
0 3 500 1 0.2 0 0
0.2 3 500 2.0±1.0 0.4 5.0±1.0 0.1
0.4 3 500 9.0±1.7 1.8 8.7±0.6 1.8
0.6 3 500 10.0±2.7 2.2 10.0±2.0 2.0
0.8 3 500 ND. ND. 18.0±2.0 3.6
Harvest
Time (h)
6 6 24 24
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J. LDH Release
The activities of LDH(Units/ml) were expressed as percentages (supernatant
activity/total cellular activity x 100%). The results showed no significant (p>0.05)
difference from day 0 to day 2 in treated cells at 0.1 mM, 0.2mM, and 0.3mM, respectively.
At 72 h there was a 3.6-fold, 3-fold, 2.7-fold, 5.2-fold increase for the 0, O.lmM, 0.2mM
and 0.3mM respectively. At 96 hr the dose related increase above the control levels was
significant (p<0.05) for the 0.3 mM treatment when compared with the control. Figure 11.
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Figure 11 shows the effect of chloroquine on cellular LDH release as an index of
membrane damage. LDH activities in lU/ml are shown as a percentage of










The cytotoxicity ofchloroquine has been demonstrated using various cell types such
as rat hepatocytes (Matsuzawa and Hostetler, 1980; Crabb, 1980), macrophages (Fedorko
et al.,1968), leukocytes (Winstanley et al., 1990), Hela S3 cells (Quarless, 1988), melanoma
cells (Morrow et al., 1989), human T-lymphoblasts (Zamora and Beck, 1986) and fibroblasts
(Fedorko et al., 1968).
The AHH-1 cells used in this experiment to assess the toxicity of chloroquine were
grown in suspension. The lymphocyte cells were selected because these cells are sensitive
to cationic amphophilic compounds. They were selected also for their unique ability to
metabolize xenobiotic agents due to the incorporation of native Cytochrome P450 enzyme,
(Crespi and Thilly, 1984; Crespi et al., 1985). These cells could serve as surrogate cells and
produce chloroquine’s metabolites to allow for a better assessment of the drug’s toxicity
under in vitro conditions. Cell growth studies showed that chloroquine kills AHH-1 cells.
Figure 3. Chloroquine indicated a linear dose-dependence in it’s cytotoxicity in relation to
these cells. The data supports the in vitro studies of Ngheim et al., 1986 who exposed
isolated thymocytes to chloroquine at concentrations of0.1 mM and 1 mM for 6 h and found
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that the number of living cells decreased by 30 % and 50 %, respectively. Chen and Leonard
(1984) also reported that cell growth was arrested when mouse cells in culture were exposed
to 0.05 mM chloroquine and cell death occurred after 1-3 days.
In the present study, chloroquine’s toxic effect on cell growth showed a time-
dependent increase in cell death of 37% and 96%, respectively at 0.2 mM and 0.6 mM
chloroquine treatments after a 80 hr exposure time. This trend continued for the 7 days the
cells were exposed to the drug. Figure 3. The increased cell death may be explained by
the primary action of chloroquine as a lysosomotropic agent, ie. its ability to accumulate in
the lysosome, take up protons to become a diprotic cationic species and ultimately cause a
transient increase in the local pH (Lullman et al, 1978; Drenckmann et al, 1976). The
disruption of proteolysis and lipolysis due to the local pH change within the acidic vesicle
serves as the primary toxic result of the action of the drug (Ohkuma and Poole, 1978; Tietz
etal., 1990). Within the lysosome or acidic vesicle, chloroquine may exhibit inhibition
of certain key enzyme ftmctions or cause the depletion ofothers or an accumulation of some
ions, enzymes or lipids vital for the maintenance of the cell. This may lead to further
biochemical and morphological alterations on the exposed cells and eventually lead to cell
death which was observed on treatment at the dose range 0.1mM or more.
B. MTT Assay
The assay provides a means for determining cell number and viability
spectrophotometrically as a function of mitochondrial activity in living cells. Mitochondrial
dehydrogenase of viable cells cleave the tetrazolium ring of the substrate reagent, yielding
purple formazan crystals which are insoluble in aqueous solution. The crystals are dissolved
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in acidified isopropanol. An increase or decrease in viable cell number results in a
concomitant change in the amount of formazan formed indicating the degree of toxicity
caused by the test chemical, chloroquine.
Essien and Ette (1985) conducted studies using rat hepatocytes in vitro. They
showed that exposure of these cells to chloroquine led to an inhibition of calcium binding
to the mitochondrial membrane, inhibition of the mitochondrial energy system and
ultimately energy depletion in the cell. Ebeigbe et al, 1986, showed that chloroquine
reduced fertility in rats by lowering spermmotility in male rats. They attributed this to the
alteration of the mitochondrial membrane resulting in a lowered capacity to bind and
accumulate calcium, a vital link in the electron transport chain. It appeared as though a
direct toxic effect of chloroquine ultimately led to the loss of energy (ATP) in the sperm
required for sperm mobility and an increase in egg fertilization. In relation to this,
Dell’Antone (1979) had also shown that lactate/pyruvate ratios increased in the liver cells
of fasted and meal-fed rats exposed to chloroquine, leading to an increase in the redox
potential of the cytosolic compartment. Chloroquine is known to cause a direct increase in
the NADH/NAD^ ratio in the cytoplasm with the inhibition of the enzyme alcohol
dehydrogenase required for the oxidation of ethanol.
The present study showed that chloroquine inhibits the mitochondrial enzyme
system in a dose-dependent manner as shown in Table 1 and supports studies by Essien and
Ette, 1985; Ette, 1986 and Dell’Antone, 1976. These results confirm the decline observed
in the estimated cell counts taken in the first experiment on cell proliferation of treated and
untreated AHH-1 cells.
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C. Acid Phosphatase Assay
Acid Phosphatase activity showed an increase after chloroquine exposure. This
increase may be associated with the ability to activate acid phosphatase in the lysosome.
Our studies revealed that acid phosphatase levels were increased in the treated cells when
compared to the control during the first 24 h of exposure before a decrease occurred at 48
h, Figure 5. The increased activity in acid phosphatase is supported by Zamora and Beck
(1986) who observed a similar increase. In addition, the studies of Zamora and Beck
revealed decreased acid phosphatase activity in vacuoles following chloroquine treatment
as shown by the lack of intense staining of acid phosphatase in these organelles.
Our study also showed that at 48 h the activity levels of the acid phosphatase in the
treated cells decreased, Figure 5. Studies by Lullman et al., 1978 using chloroquine-
exposed rat adrenocorticoid cells revealed that the acid phosphatase enzyme activity
resides in the lysosomal matrix. Upon continued exposure of the cells to chloroquine they
also observed that the cytochemically demonstrable activity of acid phosphatase was lost.
This suggests that the enzyme is released into the media or bound chemically to the
drug. This would result in a possible change in the enzyme conformation, leading to a loss
in activity of the enzyme. Our studies showed that on prolonged treatment besides the
initial increase and subsequent decrease in acid phospatase activity, cell membranes became
disrupted and lysed at doses of 0.3 mM and above. The differences in the data may be
explained on the basis of techniques in enzyme preparation.
In our studies acid phosphatase was measured using membrane-bound activity. We
observed an increased activity of the phosphatase, in AHH-1 cells of 25% and 50% at 0.4
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and 0.6 mM, respectively, over the parallel control 6 hours after exposure to chloroquine
(Figure 5). The membrane- associated acid phosphatase was shown to increase in activity
by 50% and 125%, respectively for the 0.4 and 0.6 mM treatments at 24 h. In contrast, at
48 h it was observed that for all the treatments a 33 % decline in activity had occurred when
the treated was compared to the control. These increases followed by decreases in acid
phosphatase activity of the treated cells may be due to chloroquine’s ability to activate the
synthesis of the enzyme. This may result from chloroquine’s ability to disrupt iron
homeostasis (Picot et al., 1993) which is important since, studies have shown that iron plays
a role in regulating the expression ofacid phosphatase in mammalian cells (Alcantara et al.,
1994). Chloroquine may indirectly be implicated in the secretion of the enzyme.
Future studies are needed to look at chloroquine’s interaction with acid
phosphatase. However, the data at hand could be supported by the observations of Zamora
and Beck (1985), who observed that most of the lysosomal acid phosphatase confined
within the treated cell lysosome was released with prolonged chloroquine treatment. This
indicates that the enzyme most likely leached out of the confines of the lysosomal
membrane. Our results show a time- and dose-dependent increase in the activity of the
enzyme (for the 0.6 mM treatment a 30% increase at 6 hr and a 100% increase at 24 hr).
It has been reported that alkaline phosphatase activity is similarly increased by
chloroquine (Sorimachi and Yasumura, 1986). The investigators attribute the increase in
alkaline phosphatase activity to the modulation of the protein molecule in the presence of
chloroquine. The implications of the increase in phosphatase activity during chloroquine
exposure relates to an alteration in the balance of protein kinase/protein phosphatase
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activity which can result in abnormal phosphorylation of the cell cytoskeletal, and possibly
other, proteins, ultimately leading to cell death, these effects being pronounced at higher
doses. Alterations in the cell membrane conformation and phospholipid content have been
reported with cells exposed to chloroquine (Leli and Hauser, 1987; Nosal et al., 1992).
These studies indicate that the effects and extent of damage vary based on type of cell
system or tissue, species, duration ofdmg exposure and dose level.
D. Viable, Apoptotic and Necrotic Cells
The effects of chloroquine on AHH-1 eells were observed as an increase in the
induetion ofapoptotic and necrotic cells. Cell viability determinations using flow cytometry
separated the cells into three (3) categories: viable, apoptotie, and neerotic. The percentage
ofAHH-1 cells undergoing apoptosis or necrosis or those that were viable were determined
by the preferential uptake of either one of the two stains (propidium iodide and floureseein
diacetate). The above classifications of the AHH-1 cells used in these studies have been
previously confirmed by electronic sorting of cell populations and morphological
examination (Morris et al., 1994).
The results indicate that chloroquine caused a dose-dependent decrease in cell
viability. Table 2 and 3. Also, chloroquine caused a dose-dependent increase in apoptotic
cells. It was observed that chloroquine exposure at the doses specified for our study (0-
0.6mM), led to the induction of necrosis. The process could not be described as dose-
dependent, since cells were in the proeess ofdying and forming debris in the suspension and
thus, those eells eould not be quantified. The cells were continuously exposed to
chloroquine and maintained at the same respective concentrations per flask, throughout the
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experiment. Inclusion of propidium iodide by the cells indicates membrane perforation and
this applies to the staining ofnecrotic cells. This evidence indicates that chloroquine does
disrupt the plasma membrane in treated cells. The results for the effect of chloroquine at
concentrations ranging from 0 to 0.6 mM show that at 6 hrs. Table 2, there is a decrease
in the viability of the cells earlier reflected in the decline in the cell counts.
Electron microscopic pictures of samples of chloroquine exposed cells (24 hrs)
showed a tendency towards vacuolation of the cytoplasm in some cases appearing as moth
eaten, with electron dense inclusions in exposed cells (0.3 mM to 0.6 mM), Figure 8, as
compared to the control. Figure 7, that showed few vacuoles, well defined membrane and
intact cell organelles.
A disruption of the cell membrane in the treated samples was apparent which
resulted in premature cell lysis and the release of intracellular contents most obvious at the
0.3-0.6 mM dose level. This indicates that continued exposure of the AHH-1 cells to
chloroquine residts in increased cytotoxicity shown as necrosis and apoptosis.
The cytotoxicity was shown also in the increases in the apoptotic cell population at
24 h as shown in Figure 6. At 24 h, the dose-dependent increases became evident. In Table
3, 0.6 mM showed 18.8-fold increase in the apoptotic cell population when compared to its
initial apoptotic cell population. To establish the occurrence of apoptosis in these cells DNA
fragmentation analysis both by electrophoretic and spectrophotometric methods, would be
required as well as the use ofdetailed electronmicroscopic staining techniques to establish
the features evident in apoptosis such as cell shrinkage, the condensation of chromatin, the
fragmentation of DNA into oligonucleosomal-sized fragments and the fragmentation of the
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cell resulting in the formation of apoptotic bodies which was not clearly evident in our
treated samples when the electron microscopic slides were examined.
However, the ability of chloroquine to cause apoptosis in a human B-cell line has
been shown in studies conducted by Wolvetang et al, 1996. These investigators indicated
that chloroquine, identified as a plasma membrane NADH-oxidoreductase (PMOR)
inhibitor and also an immunosuppressant, could induce apoptosis in both human B-cells
and mouse myeloid cells within 8-12 hrs, provided these cell lines did not express Bcl-2.
Bcl-2 is a protein thought to inhibit apoptosis by regulating reactive oxygen species
and calcium fluxes in the cell, inhibiting the apoptosis pathway. Their investigation
demonstrates that in the human B-cell lines the apoptotic pathway is sensitive to Bcl-2, so
when absent, apoptosis can be triggered by PMOR inhibitors. Wolvetang et al., 1996,
suggested that the ambient redox environment and the availability ofgrowth factors regulate
calcium fluxes and signal for apoptosis through the protein phosphatase, calcineurin.
An earlier study by Little and Flores (1992) gives contrasting evidence. They
proposed an alternative hypothesis to the traditional one where the activation of apoptosis
is believed to occur as a consequence of activation of an internal, genetically controlled,
program in the dying cells. They hypothesized that in hormone-induced apoptosis, the
active participation of dying cells via apoptosis may be limited to expressing surface
proteins that permit identification of cells destined to die by cytotoxic effector cells. Here
chloroquine and other immunosuppressants were found to block hormone induced apoptosis
in the tail of the bullfrog tadpole. From the results and the background given chloroquine
has been shown to induce apoptosis. A possibly mechanism of induction would be through
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the disruption of the plasma membrane redox enzyme system, which when triggered affects
plasma membrane calcium fluxes. In the absence of Bcl-2 this would signal apoptosis via
the protein phosphatase, calcineurin. The necrotic cell population showed an increase in
the treated samples, and this pathway to cell death was confirmed in the morphologically
observable lysis of the treated cells in the samples used for the preliminary morphological
assessment. The increase in the necrotic cell population at 6 h became pronounced at 24
h. Tables 2 and 3, showing a 5.5-fold and 1.5-fold increase respectively at 0.2 and 0.4 mM.
However, it may appear as if there was no change in the necrotic cell population at
0.6 mM, compared to the 0.2 and 0.4 mM at 24 h. However, cell counts at this
concentration were much lower than the previous dosages mentioned, although similar
percentages ofnecrotic cells were reported. This similarity could be attributed to the fact
that treated cells were rapidly proceeding to the necrotic stage. When the cell membrane
eventually disrupted to release cell contents seen as debris in the media, only a few cells
remained for counting, a steady-state was soon established. This ongoing process of cell
death, which was most prevalent at the higher doses (0.4-0.6mM) indicated that cells that
became debris could not be quantified. This was reflected in a decrease in the cell numbers
for those higher doses used for flow cytometric analysis, and later identified as necrotic
at >0.2 mM at 24 h of exposure. It remains to be determined if these in vitro effects occur
under in vivo conditions at normal human blood levels of chloroquine (36.6-3895 ng/ml)
when therapeutic doses have been taken.
E. Short Term Treatment Study
The results indicate that the exposure ofAHH-1 cells to 0.6 mM chloroquine did not
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produce a significant decrease in the cell numbers associated with the different stages of the
cell cycle progression (p>0.05), Table 11 and 12. No relationship could be established with
regards to chloroqtiine’s effect on the cell cycle be it dose- or time- dependency. These data
supported previous studies by Zamora and Beck (1986) who exposed human T-cell
lymphoblasts to 0.05 mM chloroquine and found that chloroquine had no effect on the cell
cycle distribution. This could be due to the fact that, chloroquine does not elicit it’s effect
by blockage of the G2+M stage of the cell cycle, although chloroquine is known to bind to
DNA and inhibit DNA and RNA polymerases (Allison et al., 1965; Cohen and Yielding,
1964). On the other hand. Figure 11 shows that the drug causes cell death by disrupting
membrane integrity, resulting in the release of cytoplasmic contents.
There is evidence to show that chloroquine affects the cell’s architecture both the
cytoplasm and the membrane, Fedorko et al, 1968. At 0.6 mM cell growth is inhibited even
after the drug is removed after a 24 h exposure, indicating that the cell’s DNA was affected,
probably via inhibition of the DNA and RNA polymerases. Studies would have to be
conducted to determine rates ofDNA synthesis in the presence and absence of the drug. It
can be seen from the data that when the drug is removed from the cells it exhibits a residual
toxicity towards the cells which wears off with time (Figure 10). The removal of the drug,
allows for the regeneration of a small core of “viable” cells or survivors that may have
overcome the drug’s toxic effects, as seen by an emerging “viable” population at the 0.6 mM
concentration, at the 144 h time point when cells had been in culture without the drug.
The lower necrotic and apoptotic cell numbers at the high dose, 0.6 mM, Figure 10,
can be attributed to the fact that most ofthe cells were dead the few remaining had become
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necrotic after the exposure and had progressively formed debris which was washed away
when the culture media was changed to remove chloroquine after the 24 hour treatment.
Some cells were probably protected by the clumping of the cells. Such clumping
was observed in the flasks of the high dose treatments (>0.3 mM). Some cells may have
been protected from chloroquine’s total toxic effects by remaining within the core of the
clump observed when the cells remained in culture. The flow cytometric analysis show that
although, viable cell numbers in the control was on the increase there is a combination of
all three populations (viable, apoptotic, and necrotic) present.
F. Micronucleus Assay
Micronucleus assay shows a linear relationship between the '^^Cs irradiated dosages
of 0, 0.5, 2.0,4.0, 6.0 Grays to the dose-dependent increases in micronuclei found per 500
binucleated cells. Table 13. This serves as a positive control for the experiment. From our
data we showed that chloroquine induced formation ofchromosomal breaks. Similarly, the
induction ofmicronuclei by chloroquine would result from a break in the arm of a diploid
chromosome during prophase, as result of the presence of the drug. The lagging piece of
chromatid observable during anaphase would separate into one of the daughter cells during
the separation of the chromatid. The result would be that at telophase when the nuclear
membrane forms around the chromatids at the poles of the daughter cell to form a nucleus,
the lagging piece of chromosomal arm would form a satellite about a third, the size of the
cell nucleus. The loss of chromosomal material sometimes leads to some deformation of
the offspring or daughter cell depending on which part of the chromosome was lost. The
diploid number of chromosome required for somatic cells may not be achieved giving rise
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to a possible disease condition in the individual or some deformity. This may contribute to
chloroquine’s teratogenic defects and apparent induction of necrosis and apoptosis.
Formation of micronuclei is also evidence for an inefficient DNA synthesizing
system in the treated cells. The data showed a dose-dependent increase in the frequency of
micronuclei induction. The effect ofchloroquine on AHH-1 cells from our results, indicates
that it is a mild inducer of micronucleus formation. However, the induction of
micronucleus by chloroquine is not time-dependent. The evidence that chloroquine is a
mild inducer ofchromosomal aberration is indicated in Table 14 and 15. These experiments
also indicate that the induction ofmicronucleus by chloroquine was dose-dependent and not
time-dependent.
G. LDH Analysis
Lactate dehydrogenase is exclusively a cytosolic enzyme catalyzing the oxidation of
NADH with pyruvate or reduction of NAD^ with lactate. Typically, cells do not actively
secrete LDH unless cellular injury has occurred (Acosta et al, 1985). Leakage of lactate
dehydrogenase and other cytoplasmic enzymes from cultured cells into the surrounding
medium is therefore evidence of cell membrane injury or breakdown in plasma membrane
permeability (Acosta et al., 1985; Danpure et al., 1984). It has also been suggested to
represent reversible or irreversible graded increases in plasma membrane permeability and
has sometimes been used to evaluate early or late toxicity in various cell culture systems
(Acosta etal., 1985).
AHH-1 cells were exposed to chloroquine continuously and activities ( in
International Units/mL) were measured and compared to the control. It would be expected
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that the control flask should release the least amount of cellular LDH, if any, since these
cells were not exposed to the toxic insult. Increases in the LDH activities at the various
time points were observed for both control and treated cells. The observations showed that
control cells had higher levels ofLDH activity than the treated until 72 h when the activity
in the 0.3 mM increased by 39.6% above the control and thereafter maintained an activity
level that was indicative of total release of the intracellular enzyme into the medium.
These results can be supported by other studies where chloroquine was shown to
cause cultured fibroblasts to secrete lysosomal acid hydrolases (Wiessmann et al., 1975;
Gonzalez-Noriega et al., 1980). The lower doses of 0.1 and 0.2 mM may have had a
stabilising effect on the cell membrane leading to the release of lower than control levels
of cellular LDH. This may be due to the stabilizing effects of chloroquine at low dose and
short durations, whereas with the high dose (>0.3 mM) and prolonged treatment the
labilizing effects or attributes of chloroquine on the cell membrane were then observed
(Weissman, 1965). The study indicates that chloroquine treatment produced membrane




This investigation examines in vitro the toxicity ofchloroquine, an antimalarial and
antimicrohial drug on a B-lymphocyte cell line . Our investigations indicate that,
(1) Chloroquine inhibits cell proliferation and cell viability
(2) Chloroquine is cytotoxic to the AHH-1 lymphoblastoid cells at concentrations
>0.1 mM.
(3) The hall marks of Chloroquine’s toxicity are:
- Increase in acid phosphatase activity which ultimately leads to cell death.
- Increase in vacuoles, possibly lysosomes/endosomes/multilamellar bodies
- Disruption ofmembrane leading to premature lysis
-Increase in the number of cells undergoing apoptosis and necrosis
(4) Chloroquine had no significant effect on cell cycle progression.
(5) Chloroquine is an inducer ofmicronucleus formation.
(6) Further Studies : In continuation ofthis work it would be necessary to (i) isolate the
apoptotic cell populations previously identified in the above treatments and to determine if
events leading to their classification as apoptotic, are the classical nuclear or biochemically
induced pathways.
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(ii) To determine if lymphocytes, in the presence of other blood elements, exposed
to chloroquine under in vivo conditions are affected similarly.
(iii) Subsequently, if lymphocytes in vivo, show similar toxic effects to chloroquine,
what could be the possible immunological implications to the host.
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